[
  {
    "symbol": "ABBV",
    "timestamp": "2025-02-04 08:49:28",
    "names": {
      "long": "AbbVie Inc.",
      "short": "AbbVie Inc.",
      "polygon": "ABBVIE INC."
    },
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "description": "AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).",
    "branding": {
      "icon_url": "https://api.polygon.io/v1/reference/company-branding/YWJidmllaW52ZXN0b3IuY29t/images/2024-10-01_icon.png?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq",
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/YWJidmllaW52ZXN0b3IuY29t/images/2024-10-01_logo.svg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "investing_url": "https://www.investing.com/equities/abbvie-inc",
    "price": 189.93,
    "priceChange": -0.11044493531081284,
    "openPrice": 187.63,
    "prevClose": 190.14,
    "dayHigh": 190.14,
    "dayLow": 187.05,
    "volume": 2144122.0,
    "prevVolume": 9562053.0,
    "volumeMetrics": {
      "recentVolumes": [
        3547564.0,
        4929249.0,
        11636929.0,
        9562053.0,
        2144122.0
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        38.95,
        136.08,
        -17.83,
        -77.58
      ],
      "averageVolume": 5980226.55,
      "volumeChange": -77.58,
      "volumeVsAvg": -64.15
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 5980226.55
    },
    "fiftyTwoWeekHigh": 207.32,
    "fiftyTwoWeekLow": 153.58,
    "highProximityPct": 8.387999228246183,
    "marketCap": 333759792805.01,
    "insiderActivity": {
      "recent_trades": 2,
      "net_shares": -3600,
      "notable_trades": [
        {
          "date": "2024-12-16",
          "insider": "BUCKBEE KEVIN K",
          "position": "Officer",
          "type": "Sale",
          "shares": 1800,
          "value": 168300.0,
          "price_per_share": 93.5
        },
        {
          "date": "2024-12-16",
          "insider": "BUCKBEE KEVIN K",
          "position": "Officer",
          "type": "Sale",
          "shares": 1800,
          "value": 310032.0,
          "price_per_share": 172.24
        }
      ],
      "summary": {
        "total_sales": 3600,
        "total_purchases": 0,
        "total_awards": 0,
        "sales_count": 2,
        "purchases_count": 0,
        "awards_count": 0,
        "total_value": {
          "sales": 478332.0,
          "purchases": 0.0,
          "awards": 0.0
        }
      },
      "latest_date": "2024-12-16"
    },
    "recentNews": [
      {
        "title": "Orphan Designated Drugs Market Analysis: Key Trends, Players and Forecasts for Future Growth",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2025-02-03T09:52:00Z",
        "url": "https://www.globenewswire.com/news-release/2025/02/03/3019270/28124/en/Orphan-Designated-Drugs-Market-Analysis-Key-Trends-Players-and-Forecasts-for-Future-Growth.html",
        "type": "ABBV"
      },
      {
        "title": "Want $1 Million in Retirement? 2 Stocks to Buy Now and Hold for Decades.",
        "publisher": "The Motley Fool",
        "timestamp": "2025-02-01T11:05:00Z",
        "url": "https://www.fool.com/investing/2025/02/01/want-1-million-in-retirement-2-stocks-to-buy-now-a/?source=iedfolrf0000001",
        "type": "ABBV"
      },
      {
        "title": "FDA Approval of Eli Lilly\u2019s Omvoh for Crohn\u2019s Disease Adds a New Option, but Uptake May be Hampered by US Gastroenterologists\u2019 Brand Preferences Among the IL-23 Class, According to Spherix Global Insights",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2025-01-31T18:52:00Z",
        "url": "https://www.globenewswire.com/news-release/2025/01/31/3018975/0/en/FDA-Approval-of-Eli-Lilly-s-Omvoh-for-Crohn-s-Disease-Adds-a-New-Option-but-Uptake-May-be-Hampered-by-US-Gastroenterologists-Brand-Preferences-Among-the-IL-23-Class-According-to-Sp.html",
        "type": "LLY"
      },
      {
        "title": "Why AbbVie Stock Is Jumping Today",
        "publisher": "The Motley Fool",
        "timestamp": "2025-01-31T17:42:03Z",
        "url": "https://www.fool.com/investing/2025/01/31/why-abbvie-stock-is-jumping-today/?source=iedfolrf0000001",
        "type": "ABBV"
      },
      {
        "title": "I Own 4 High-Yield Dividend Stocks. Here's Why I Own Each One.",
        "publisher": "The Motley Fool",
        "timestamp": "2025-01-28T11:15:00Z",
        "url": "https://www.fool.com/investing/2025/01/28/i-own-4-high-yield-dividend-stocks-heres-why-i-own/?source=iedfolrf0000001",
        "type": "ABBV"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": 79.3375,
        "forwardPE": 13.744868
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 2,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": true,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  },
  {
    "symbol": "ABCL",
    "timestamp": "2025-02-04 08:49:30",
    "names": {
      "long": "AbCellera Biologics Inc.",
      "short": "AbCellera Biologics Inc.",
      "polygon": "AbCellera Biologics Inc. Common Shares"
    },
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "description": "AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.",
    "branding": {
      "icon_url": "https://api.polygon.io/v1/reference/company-branding/YWJjZWxsZXJhLmNvbQ/images/2024-10-01_icon.jpeg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq",
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/YWJjZWxsZXJhLmNvbQ/images/2024-10-01_logo.svg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "investing_url": "https://www.investing.com/equities/abcellera-biologics",
    "price": 3.175,
    "priceChange": 3.0844155844155763,
    "openPrice": 3.08,
    "prevClose": 3.08,
    "dayHigh": 3.24,
    "dayLow": 3.065,
    "volume": 1071528.0,
    "prevVolume": 4505215.0,
    "volumeMetrics": {
      "recentVolumes": [
        4076911.0,
        2179800.0,
        3081464.0,
        4505215.0,
        1071528.0
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        -46.53,
        41.36,
        46.2,
        -76.22
      ],
      "averageVolume": 3101199.3333333335,
      "volumeChange": -76.22,
      "volumeVsAvg": -65.45
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 3101199.3333333335
    },
    "fiftyTwoWeekHigh": 5.46,
    "fiftyTwoWeekLow": 2.335,
    "highProximityPct": 41.849816849816854,
    "marketCap": 943695264.5999999,
    "insiderActivity": {
      "recent_trades": 2,
      "net_shares": 342125,
      "notable_trades": [
        {
          "date": "2024-11-25",
          "insider": "HANSEN CARL L.G.",
          "position": "Chief Executive Officer",
          "type": "Stock Award",
          "shares": 56125,
          "value": 151538.0,
          "price_per_share": 2.7000089086859687
        }
      ],
      "summary": {
        "total_sales": 0,
        "total_purchases": 286000,
        "total_awards": 56125,
        "sales_count": 0,
        "purchases_count": 1,
        "awards_count": 1,
        "total_value": {
          "sales": 0.0,
          "purchases": 0.0,
          "awards": 151538.0
        }
      },
      "latest_date": "2024-12-04"
    },
    "recentNews": [
      {
        "title": "Down 57%, Is AbCellera Biologics a Buy on the Dip?",
        "publisher": "The Motley Fool",
        "timestamp": "2024-06-13T09:40:00Z",
        "url": "https://www.fool.com/investing/2024/06/13/down-57-is-abcellera-biologics-a-buy-on-the-dip/",
        "type": "ABCL"
      },
      {
        "title": "AbCellera Biologics (ABCL) Q1 2024 Earnings Call Transcript",
        "publisher": "The Motley Fool",
        "timestamp": "2024-05-08T08:30:12Z",
        "url": "https://www.fool.com/earnings/call-transcripts/2024/05/08/abcellera-biologics-abcl-q1-2024-earnings-call-tra/",
        "type": "ABCL"
      },
      {
        "title": "AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates",
        "publisher": "Zacks Investment Research",
        "timestamp": "2024-05-07T22:05:07Z",
        "url": "https://www.zacks.com/stock/news/2270061/abcellera-biologics-inc-abcl-reports-q1-loss-misses-revenue-estimates",
        "type": "ABCL"
      },
      {
        "title": "Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release",
        "publisher": "Zacks Investment Research",
        "timestamp": "2024-05-01T14:01:28Z",
        "url": "https://www.zacks.com/stock/news/2266059/cytokinetics-cytk-may-report-negative-earnings-know-the-trend-ahead-of-next-weeks-release",
        "type": "CYTK"
      },
      {
        "title": "Analysts Estimate AbCellera Biologics Inc. (ABCL) to Report a Decline in Earnings: What to Look Out for",
        "publisher": "Zacks Investment Research",
        "timestamp": "2024-04-30T14:01:05Z",
        "url": "https://www.zacks.com/stock/news/2265111/analysts-estimate-abcellera-biologics-inc-abcl-to-report-a-decline-in-earnings-what-to-look-out-for",
        "type": "ABCL"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": null,
        "forwardPE": -4.7037034
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 2,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": true,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  },
  {
    "symbol": "ABUS",
    "timestamp": "2025-02-04 08:49:33",
    "names": {
      "long": "Arbutus Biopharma Corporation",
      "short": "Arbutus Biopharma Corporation",
      "polygon": "Arbutus Biopharma Corporation Common Stock"
    },
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "description": "Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.",
    "branding": {
      "icon_url": "https://api.polygon.io/v1/reference/company-branding/YXJidXR1c2Jpby5jb20/images/2024-10-01_icon.jpeg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq",
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/YXJidXR1c2Jpby5jb20/images/2024-10-01_logo.svg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "investing_url": "https://www.investing.com/equities/tekmira-pharmaceuticals-corp",
    "price": 3.315,
    "priceChange": 1.0670731707317118,
    "openPrice": 3.27,
    "prevClose": 3.28,
    "dayHigh": 3.34,
    "dayLow": 3.25,
    "volume": 99569,
    "prevVolume": 698849,
    "volumeMetrics": {
      "recentVolumes": [
        559459,
        364778,
        671508,
        698849,
        99569
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        -34.8,
        84.09,
        4.07,
        -85.75
      ],
      "averageVolume": 808385.0666666667,
      "volumeChange": -85.75,
      "volumeVsAvg": -87.68
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 808385.0666666667
    },
    "fiftyTwoWeekHigh": 4.72,
    "fiftyTwoWeekLow": 2.3,
    "highProximityPct": 29.76694915254237,
    "marketCap": 619205055.12,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": [],
      "summary": {
        "total_sales": 0,
        "total_purchases": 0,
        "total_awards": 0,
        "sales_count": 0,
        "purchases_count": 0,
        "awards_count": 0
      }
    },
    "recentNews": [
      {
        "title": "Ultragenyx (RARE) Moves 7.8% Higher: Will This Strength Last?",
        "publisher": "Zacks Investment Research",
        "timestamp": "2024-06-13T09:12:00Z",
        "url": "https://www.zacks.com/stock/news/2287612/ultragenyx-rare-moves-78-higher-will-this-strength-last",
        "type": "RARE"
      },
      {
        "title": "Treatment with Arbutus\u2019 Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-06-06T15:15:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/06/06/2894849/14025/en/Treatment-with-Arbutus-Imdusiran-and-VTP-300-Achieves-Statistical-Significance-in-Lowering-HBsAg-Levels.html",
        "type": "ABUS"
      },
      {
        "title": "Arbutus\u2019 Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-06-05T06:30:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/06/05/2893578/14025/en/Arbutus-Imdusiran-with-Short-Course-Interferon-Achieves-Sustained-Undetectable-HBsAg-a-Necessity-for-HBV-Functional-Cure.html",
        "type": "ABUS"
      },
      {
        "title": "Arbutus to Participate in Jefferies Global Healthcare Conference",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-05-29T11:30:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/05/29/2889732/14025/en/Arbutus-to-Participate-in-Jefferies-Global-Healthcare-Conference.html",
        "type": "ABUS"
      },
      {
        "title": "Arbutus to Present Imdusiran Data at EASL Congress 2024",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-05-22T06:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/05/22/2886180/14025/en/Arbutus-to-Present-Imdusiran-Data-at-EASL-Congress-2024.html",
        "type": "ABUS"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": null,
        "forwardPE": -7.074468
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  },
  {
    "symbol": "ACLS",
    "timestamp": "2025-02-04 08:49:36",
    "names": {
      "long": "Axcelis Technologies, Inc.",
      "short": "Axcelis Technologies, Inc.",
      "polygon": "Axcelis Technologies Inc"
    },
    "sector": "Technology",
    "industry": "Semiconductor Equipment & Materials",
    "description": "Axcelis Technologies Inc designs, manufactures and services ion implantation and other processing equipment used in the fabrication of semiconductor chips. In addition to equipment, the company provide aftermarket lifecycle products and services, including used tools, spare parts, equipment upgrades, maintenance services and customer training. Geographically, the group has a business presence in North America, Asia Pacific and Europe, of which key revenue is derived from the Asia Pacific.",
    "branding": {
      "icon_url": "https://api.polygon.io/v1/reference/company-branding/YXhjZWxpcy5jb20/images/2024-10-01_icon.jpeg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq",
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/YXhjZWxpcy5jb20/images/2024-10-01_logo.svg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "investing_url": "https://www.investing.com/equities/axcelis-tech",
    "price": 67.39,
    "priceChange": 2.5722983257229797,
    "openPrice": 65.51,
    "prevClose": 65.7,
    "dayHigh": 67.39,
    "dayLow": 65.51,
    "volume": 100491,
    "prevVolume": 933772,
    "volumeMetrics": {
      "recentVolumes": [
        355555,
        364759,
        843231,
        933772,
        100491
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        2.59,
        131.17,
        10.74,
        -89.24
      ],
      "averageVolume": 584965.65,
      "volumeChange": -89.24,
      "volumeVsAvg": -82.82
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 584965.65
    },
    "fiftyTwoWeekHigh": 158.61,
    "fiftyTwoWeekLow": 64.18,
    "highProximityPct": 57.51213668747241,
    "marketCap": 2147646247.659,
    "insiderActivity": {
      "recent_trades": 1,
      "net_shares": 11440,
      "notable_trades": [],
      "summary": {
        "total_sales": 0,
        "total_purchases": 11440,
        "total_awards": 0,
        "sales_count": 0,
        "purchases_count": 1,
        "awards_count": 0,
        "total_value": {
          "sales": 0.0,
          "purchases": 0.0,
          "awards": 0.0
        }
      },
      "latest_date": "2024-12-16"
    },
    "recentNews": [
      {
        "title": "3 Must-Watch Semiconductor Stocks as Nvidia Takes a Breather",
        "publisher": "Investing.com",
        "timestamp": "2025-01-21T12:22:00Z",
        "url": "https://www.investing.com/analysis/3-mustwatch-semiconductor-stocks-as-nvidia-takes-a-breather-200656455",
        "type": "AMD"
      },
      {
        "title": "5 Super Semiconductor Stocks to Buy Hand Over Fist Heading Into 2025",
        "publisher": "The Motley Fool",
        "timestamp": "2024-10-04T08:02:00Z",
        "url": "https://www.fool.com/investing/2024/10/04/5-semiconductor-stocks-buy-hand-fist-heading-2025/?source=iedfolrf0000001",
        "type": "NVDA"
      },
      {
        "title": "1 Super Semiconductor Stock to Buy Hand Over Fist for the AI Revolution",
        "publisher": "The Motley Fool",
        "timestamp": "2024-09-20T09:28:00Z",
        "url": "https://www.fool.com/investing/2024/09/20/1-semiconductor-stock-buy-hand-fist-ai-revolution/?source=iedfolrf0000001",
        "type": "ACLS"
      },
      {
        "title": "2 EV Chip Stocks Down 34% and 45% That Could Become Stealth Artificial Intelligence (AI) Plays",
        "publisher": "The Motley Fool",
        "timestamp": "2024-08-28T08:55:00Z",
        "url": "https://www.fool.com/investing/2024/08/28/2-ev-chip-stocks-down-34-and-45-become-ai-plays/?source=iedfolrf0000001",
        "type": "ACLS"
      },
      {
        "title": "S&P 500 Sell-Off: 1 Bargain-Basement Semiconductor Stock to Buy Right Now",
        "publisher": "The Motley Fool",
        "timestamp": "2024-08-08T09:53:00Z",
        "url": "https://www.fool.com/investing/2024/08/08/sp-500-sell-off-1-semiconductor-stock-buy-right/?source=iedfolrf0000001",
        "type": "ACLS"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": 9.968934,
        "forwardPE": 14.2173
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  },
  {
    "symbol": "ADMA",
    "timestamp": "2025-02-04 08:49:38",
    "names": {
      "long": "ADMA Biologics, Inc.",
      "short": "ADMA Biologics Inc",
      "polygon": "ADMA Biologics, Inc."
    },
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "description": "ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.",
    "branding": {
      "icon_url": "https://api.polygon.io/v1/reference/company-branding/YWRtYWJpb2xvZ2ljcy5jb20/images/2024-10-01_icon.jpeg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq",
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/YWRtYWJpb2xvZ2ljcy5jb20/images/2024-10-01_logo.svg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "investing_url": "https://www.investing.com/equities/adma-biologics-inc",
    "price": 16.45,
    "priceChange": -0.12143290831815165,
    "openPrice": 16.69,
    "prevClose": 16.47,
    "dayHigh": 16.75,
    "dayLow": 16.12,
    "volume": 675936,
    "prevVolume": 2442957.0,
    "volumeMetrics": {
      "recentVolumes": [
        2070973.0,
        2135981.0,
        2409267.0,
        2442957.0,
        675936
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        3.14,
        12.79,
        1.4,
        -72.33
      ],
      "averageVolume": 2595359.45,
      "volumeChange": -72.33,
      "volumeVsAvg": -73.96
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 2595359.45
    },
    "fiftyTwoWeekHigh": 23.64,
    "fiftyTwoWeekLow": 5.02,
    "highProximityPct": 30.414551607445013,
    "marketCap": 3879164051.73,
    "insiderActivity": {
      "recent_trades": 3,
      "net_shares": -54967,
      "notable_trades": [
        {
          "date": "2024-11-22",
          "insider": "GROSSMAN ADAM S",
          "position": "Chief Executive Officer",
          "type": "Sale",
          "shares": 48967,
          "value": 1033204.0,
          "price_per_share": 21.10000612657504
        },
        {
          "date": "2024-11-22",
          "insider": "TADE BRAD L",
          "position": "Chief Financial Officer",
          "type": "Sale",
          "shares": 15000,
          "value": 317250.0,
          "price_per_share": 21.15
        }
      ],
      "summary": {
        "total_sales": 63967,
        "total_purchases": 0,
        "total_awards": 9000,
        "sales_count": 2,
        "purchases_count": 0,
        "awards_count": 1,
        "total_value": {
          "sales": 1350454.0,
          "purchases": 0.0,
          "awards": 97200.0
        }
      },
      "latest_date": "2024-11-27"
    },
    "recentNews": [
      {
        "title": "BFA Law is Investigating ADMA BIOLOGICS for Securities Fraud after Stock Plummets 20%; Contact the Firm if You Suffered Losses (Nasdaq:ADMA)",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-11-02T10:18:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/11/02/2973618/0/en/BFA-Law-is-Investigating-ADMA-BIOLOGICS-for-Securities-Fraud-after-Stock-Plummets-20-Contact-the-Firm-if-You-Suffered-Losses-Nasdaq-ADMA.html",
        "type": "ADMA"
      },
      {
        "title": "ADMA FRAUD ALERT: BFA Law Notifies ADMA Biologics Investors of Ongoing Securities Fraud Investigation after Auditor Resigns and Urges You to Contact the Firm (Nasdaq:ADMA)",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-10-27T12:06:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/10/27/2969720/0/en/ADMA-FRAUD-ALERT-BFA-Law-Notifies-ADMA-Biologics-Investors-of-Ongoing-Securities-Fraud-Investigation-after-Auditor-Resigns-and-Urges-You-to-Contact-the-Firm-Nasdaq-ADMA.html",
        "type": "ADMA"
      },
      {
        "title": "ADMA INVESTIGATION UPDATE: ADMA Biologics Investors are Notified of Securities Fraud Investigation into Auditor Resignation; Contact BFA Law if You Lost Money (Nasdaq:ADMA)",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-10-19T10:28:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/10/19/2965788/0/en/ADMA-INVESTIGATION-UPDATE-ADMA-Biologics-Investors-are-Notified-of-Securities-Fraud-Investigation-into-Auditor-Resignation-Contact-BFA-Law-if-You-Lost-Money-Nasdaq-ADMA.html",
        "type": "ADMA"
      },
      {
        "title": "ADMA Biologics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-10-17T15:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/10/17/2965053/23044/en/ADMA-Biologics-ALERT-Securities-Fraud-Investigation-by-Block-Leviton-Could-Allow-Investors-to-Recover-Losses.html",
        "type": "ADMA"
      },
      {
        "title": "ADMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into ADMA Biologics Inc and Encourages Investors to Contact the Firm",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-10-15T20:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/10/15/2963607/9788/en/ADMA-INVESTOR-ALERT-Bronstein-Gewirtz-and-Grossman-LLC-Announces-an-Investigation-into-ADMA-Biologics-Inc-and-Encourages-Investors-to-Contact-the-Firm.html",
        "type": "ADMA"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": 61.259262,
        "forwardPE": 23.971016
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 2,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": true,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  },
  {
    "symbol": "ADVM",
    "timestamp": "2025-02-04 08:49:41",
    "names": {
      "long": "Adverum Biotechnologies, Inc.",
      "short": "Adverum Biotechnologies, Inc.",
      "polygon": "Adverum Biotechnologies, Inc. Common Stock"
    },
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "description": "Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.",
    "branding": {
      "icon_url": "https://api.polygon.io/v1/reference/company-branding/YWR2ZXJ1bS5jb20/images/2024-10-01_icon.jpeg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq",
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/YWR2ZXJ1bS5jb20/images/2024-10-01_logo.png?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "investing_url": "https://www.investing.com/equities/avalanche-biotec",
    "price": 4.45,
    "priceChange": 4.460093896713625,
    "openPrice": 4.24,
    "prevClose": 4.26,
    "dayHigh": 4.54,
    "dayLow": 4.24,
    "volume": 16161,
    "prevVolume": 139823,
    "volumeMetrics": {
      "recentVolumes": [
        63908,
        130479,
        145690,
        139823,
        16161
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        104.17,
        11.66,
        -4.03,
        -88.44
      ],
      "averageVolume": 210789.35,
      "volumeChange": -88.44,
      "volumeVsAvg": -92.33
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 210789.35
    },
    "fiftyTwoWeekHigh": 29.7,
    "fiftyTwoWeekLow": 4.01,
    "highProximityPct": 85.01683501683502,
    "marketCap": 93403058.87,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": [],
      "summary": {
        "total_sales": 0,
        "total_purchases": 0,
        "total_awards": 0,
        "sales_count": 0,
        "purchases_count": 0,
        "awards_count": 0
      }
    },
    "recentNews": [
      {
        "title": "Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-10-22T17:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/10/22/2967216/0/en/Gene-Therapy-Clinical-Trial-Pipeline-Gains-Momentum-180-Companies-Lead-the-Charge-in-Pioneering-New-Treatments-DelveInsight.html",
        "type": "RARE"
      },
      {
        "title": "What's in Store for ADMA Biologics (ADMA) in Q2 Earnings? - Zacks Investment Research",
        "publisher": "Zacks Investment Research",
        "timestamp": "2024-07-22T14:01:42Z",
        "url": "https://www.zacks.com/stock/news/2306129/whats-in-store-for-adma-biologics-adma-in-q2-earnings",
        "type": "ADMA"
      },
      {
        "title": "Adverum biotechnologies executive buys shares worth over $1.7 million By Investing.com - Investing.com Australia",
        "publisher": "Investing.com",
        "timestamp": "2024-07-19T02:01:07Z",
        "url": "https://au.investing.com/news/company-news/adverum-biotechnologies-executive-buys-shares-worth-over-17-million-93CH-3348309",
        "type": "ADVM"
      },
      {
        "title": "Why Bloom Energy Group Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket - Benzinga",
        "publisher": "Benzinga",
        "timestamp": "2024-07-17T10:03:31Z",
        "url": "https://www.benzinga.com/news/24/07/39810902/why-bloom-energy-group-shares-are-trading-higher-by-12-here-are-20-stocks-moving-premarket",
        "type": "BE"
      },
      {
        "title": "Adverum Biotechnologies Presents Positive Ixo-vec Clinical - GlobeNewswire",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-07-17T06:46:52Z",
        "url": "https://www.globenewswire.com/news-release/2024/07/17/2914283/32452/en/Adverum-Biotechnologies-Presents-Positive-Ixo-vec-Clinical-Data-from-the-26-Week-Interim-Analysis-of-the-LUNA-Phase-2-Trial-at-the-2024-ASRS-Annual-Meeting.html",
        "type": "ADVM"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": null,
        "forwardPE": -1.0307448
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  },
  {
    "symbol": "AGEN",
    "timestamp": "2025-02-04 08:49:43",
    "names": {
      "long": "Agenus Inc.",
      "short": "Agenus Inc.",
      "polygon": "Agenus Inc."
    },
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "description": "Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).",
    "branding": {
      "icon_url": "https://api.polygon.io/v1/reference/company-branding/YWdlbnVzYmlvLmNvbQ/images/2024-10-01_icon.jpeg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq",
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/YWdlbnVzYmlvLmNvbQ/images/2024-10-01_logo.svg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "investing_url": "https://www.investing.com/equities/agenus-inc",
    "price": 3.51,
    "priceChange": 0.0,
    "openPrice": 3.51,
    "prevClose": 3.51,
    "dayHigh": 3.6,
    "dayLow": 3.4,
    "volume": 146864,
    "prevVolume": 437759,
    "volumeMetrics": {
      "recentVolumes": [
        320770,
        302070,
        686464,
        437759,
        146864
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        -5.83,
        127.25,
        -36.23,
        -66.45
      ],
      "averageVolume": 535885.9166666666,
      "volumeChange": -66.45,
      "volumeVsAvg": -72.59
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 535885.9166666666
    },
    "fiftyTwoWeekHigh": 19.69,
    "fiftyTwoWeekLow": 2.5,
    "highProximityPct": 82.17369222955814,
    "marketCap": 80280568.8,
    "insiderActivity": {
      "recent_trades": 7,
      "net_shares": 31766,
      "notable_trades": [],
      "summary": {
        "total_sales": 0,
        "total_purchases": 0,
        "total_awards": 31766,
        "sales_count": 0,
        "purchases_count": 0,
        "awards_count": 7,
        "total_value": {
          "sales": 0.0,
          "purchases": 0.0,
          "awards": 97797.0
        }
      },
      "latest_date": "2025-01-24"
    },
    "recentNews": [
      {
        "title": "MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2025-01-23T19:13:00Z",
        "url": "https://www.globenewswire.com/news-release/2025/01/23/3014550/0/en/MiNK-Therapeutics-Targets-Immune-Reconstitution-to-Combat-Advanced-Gastroesophageal-Cancers-with-Novel-Combination-of-Allo-iNKTs-plus-BOT-BAL-at-ASCO-GI.html",
        "type": "INKT"
      },
      {
        "title": "Agenus (AGEN) Q3 2024 Earnings Call Transcript",
        "publisher": "The Motley Fool",
        "timestamp": "2024-11-12T17:15:14Z",
        "url": "https://www.fool.com/earnings/call-transcripts/2024/11/12/agenus-agen-q3-2024-earnings-call-transcript/?source=iedfolrf0000001",
        "type": "AGEN"
      },
      {
        "title": "DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors of Agenus to Contact Us to Have Their Losses Evaluated Today",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-11-02T11:45:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/11/02/2973626/683/en/DEADLINE-ALERT-Faruqi-Faruqi-LLP-Encourages-Investors-of-Agenus-to-Contact-Us-to-Have-Their-Losses-Evaluated-Today.html",
        "type": "AGEN"
      },
      {
        "title": "Agenus Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - AGEN",
        "publisher": "Benzinga",
        "timestamp": "2024-10-31T09:45:00Z",
        "url": "https://www.benzinga.com/pressreleases/24/10/n41647023/agenus-inc-sued-for-securities-law-violations-investors-should-contact-the-gross-law-firm-for-more",
        "type": "AGEN"
      },
      {
        "title": "Agenus Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. November 5, 2024 Deadline to file Lead Plaintiff Motion",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-10-30T22:54:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/10/30/2972201/0/en/Agenus-Inc-Investors-Please-contact-the-Portnoy-Law-Firm-to-recover-your-losses-November-5-2024-Deadline-to-file-Lead-Plaintiff-Motion.html",
        "type": "AGEN"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": null,
        "forwardPE": -0.4859566
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  },
  {
    "symbol": "ALKS",
    "timestamp": "2025-02-04 08:49:46",
    "names": {
      "long": "Alkermes plc",
      "short": "Alkermes plc",
      "polygon": "Alkermes Inc. plc"
    },
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "description": "Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in\u00a0therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.",
    "branding": {
      "icon_url": "https://api.polygon.io/v1/reference/company-branding/YWxrZXJtZXMuY29t/images/2024-10-01_icon.jpeg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq",
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/YWxrZXJtZXMuY29t/images/2024-10-01_logo.svg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "investing_url": "https://www.investing.com/equities/alkermes-plc",
    "price": 31.37,
    "priceChange": 1.9830949284785415,
    "openPrice": 30.73,
    "prevClose": 30.76,
    "dayHigh": 31.46,
    "dayLow": 30.51,
    "volume": 200692,
    "prevVolume": 1195581.0,
    "volumeMetrics": {
      "recentVolumes": [
        800218,
        920721,
        1889896.0,
        1195581.0,
        200692
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        15.06,
        105.26,
        -36.74,
        -83.21
      ],
      "averageVolume": 1438447.4166666667,
      "volumeChange": -83.21,
      "volumeVsAvg": -86.05
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 1438447.4166666667
    },
    "fiftyTwoWeekHigh": 32.88,
    "fiftyTwoWeekLow": 22.9,
    "highProximityPct": 4.592457420924578,
    "marketCap": 5276320476.98,
    "insiderActivity": {
      "recent_trades": 11,
      "net_shares": -435367,
      "notable_trades": [
        {
          "date": "2025-01-30",
          "insider": "HOPKINSON CRAIG C",
          "position": "Officer",
          "type": "Sale",
          "shares": 100918,
          "value": 3234382.0,
          "price_per_share": 32.04960462950118
        },
        {
          "date": "2025-01-30",
          "insider": "HOPKINSON CRAIG C",
          "position": "Officer",
          "type": "Sale",
          "shares": 97632,
          "value": 2169137.0,
          "price_per_share": 22.21747992461488
        },
        {
          "date": "2024-12-09",
          "insider": "HOPKINSON CRAIG C",
          "position": "Officer",
          "type": "Sale",
          "shares": 61151,
          "value": 1961406.0,
          "price_per_share": 32.07479844973917
        },
        {
          "date": "2024-12-09",
          "insider": "HOPKINSON CRAIG C",
          "position": "Officer",
          "type": "Sale",
          "shares": 48997,
          "value": 1112259.0,
          "price_per_share": 22.700553095087454
        },
        {
          "date": "2024-12-05",
          "insider": "HOPKINSON CRAIG C",
          "position": "Officer",
          "type": "Sale",
          "shares": 9221,
          "value": 290462.0,
          "price_per_share": 31.50005422405379
        },
        {
          "date": "2024-12-04",
          "insider": "HOPKINSON CRAIG C",
          "position": "Officer",
          "type": "Sale",
          "shares": 14349,
          "value": 441550.0,
          "price_per_share": 30.772179245940485
        },
        {
          "date": "2024-11-27",
          "insider": "NICHOLS CHRISTIAN TODD",
          "position": "Officer",
          "type": "Sale",
          "shares": 5208,
          "value": 151813.0,
          "price_per_share": 29.149961597542244
        },
        {
          "date": "2024-11-11",
          "insider": "HOPKINSON CRAIG C",
          "position": "Officer",
          "type": "Sale",
          "shares": 58996,
          "value": 1774576.0,
          "price_per_share": 30.07959861685538
        },
        {
          "date": "2024-11-11",
          "insider": "HOPKINSON CRAIG C",
          "position": "Officer",
          "type": "Sale",
          "shares": 43058,
          "value": 862452.0,
          "price_per_share": 20.030006038366853
        }
      ],
      "summary": {
        "total_sales": 442221,
        "total_purchases": 0,
        "total_awards": 6854,
        "sales_count": 10,
        "purchases_count": 0,
        "awards_count": 1,
        "total_value": {
          "sales": 12083745.0,
          "purchases": 0.0,
          "awards": 60601.0
        }
      },
      "latest_date": "2025-01-30"
    },
    "recentNews": [
      {
        "title": "6 Analysts Assess Alkermes: What You Need To Know - Benzinga",
        "publisher": "Benzinga",
        "timestamp": "2024-07-15T21:00:44Z",
        "url": "https://www.benzinga.com/insights/analyst-ratings/24/07/39782584/6-analysts-assess-alkermes-what-you-need-to-know",
        "type": "ALKS"
      },
      {
        "title": "Orchestra BioMed Holdings, Inc. (OBIO) Stock Jumps 7.3%: Will It Continue to Soar?",
        "publisher": "Zacks Investment Research",
        "timestamp": "2024-06-24T12:07:00Z",
        "url": "https://www.zacks.com/stock/news/2291977/orchestra-biomed-holdings-inc-obio-stock-jumps-73-will-it-continue-to-soar",
        "type": "OBIO"
      },
      {
        "title": "Why Is Alkermes (ALKS) Down 2.7% Since Last Earnings Report?",
        "publisher": "Zacks Investment Research",
        "timestamp": "2024-05-31T15:31:42Z",
        "url": "https://www.zacks.com/stock/news/2282178/why-is-alkermes-alks-down-27-since-last-earnings-report",
        "type": "ALKS"
      },
      {
        "title": "Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?",
        "publisher": "Zacks Investment Research",
        "timestamp": "2024-05-27T10:20:07Z",
        "url": "https://www.zacks.com/stock/news/2279192/should-you-invest-in-the-invesco-sp-smallcap-health-care-etf-psch",
        "type": "PSCH"
      },
      {
        "title": "6 Analysts Assess Alkermes: What You Need To Know",
        "publisher": "Benzinga",
        "timestamp": "2024-05-23T16:00:52Z",
        "url": "https://www.benzinga.com/insights/analyst-ratings/24/05/38989706/6-analysts-assess-alkermes-what-you-need-to-know",
        "type": "ALKS"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": 13.703056,
        "forwardPE": 18.17192
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": true,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": true
    }
  },
  {
    "symbol": "AMPH",
    "timestamp": "2025-02-04 08:49:49",
    "names": {
      "long": "Amphastar Pharmaceuticals, Inc.",
      "short": "Amphastar Pharmaceuticals, Inc.",
      "polygon": "Amphastar Pharmaceuticals, Inc."
    },
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "description": "Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses\u00a0on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.",
    "branding": {
      "icon_url": null,
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/YW1waGFzdGFyLmNvbQ/images/2024-10-01_logo.svg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "investing_url": "https://www.investing.com/equities/amphastar-p",
    "price": 33.43,
    "priceChange": 0.119796346211438,
    "openPrice": 32.415,
    "prevClose": 33.39,
    "dayHigh": 33.76,
    "dayLow": 32.25,
    "volume": 187979,
    "prevVolume": 596206,
    "volumeMetrics": {
      "recentVolumes": [
        416557,
        420390,
        511452,
        596206,
        187979
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        0.92,
        21.66,
        16.57,
        -68.47
      ],
      "averageVolume": 538560.4,
      "volumeChange": -68.47,
      "volumeVsAvg": -65.1
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 538560.4
    },
    "fiftyTwoWeekHigh": 56.45,
    "fiftyTwoWeekLow": 32.25,
    "highProximityPct": 40.77945084145262,
    "marketCap": 1587168103.33,
    "insiderActivity": {
      "recent_trades": 11,
      "net_shares": 248910,
      "notable_trades": [
        {
          "date": "2024-12-13",
          "insider": "ZHOU RONG",
          "position": "Officer",
          "type": "Sale",
          "shares": 15000,
          "value": 672815.0,
          "price_per_share": 44.85433333333334
        },
        {
          "date": "2024-12-13",
          "insider": "ZHOU RONG",
          "position": "Officer",
          "type": "Stock Award",
          "shares": 15000,
          "value": 169950.0,
          "price_per_share": 11.33
        },
        {
          "date": "2024-12-09",
          "insider": "PRINS RICHARD K",
          "position": "Director",
          "type": "Sale",
          "shares": 10000,
          "value": 437702.0,
          "price_per_share": 43.7702
        },
        {
          "date": "2024-12-09",
          "insider": "PRINS RICHARD K",
          "position": "Director",
          "type": "Stock Award",
          "shares": 10000,
          "value": 195200.0,
          "price_per_share": 19.52
        },
        {
          "date": "2024-11-12",
          "insider": "PRINS RICHARD K",
          "position": "Director",
          "type": "Sale",
          "shares": 5000,
          "value": 243986.0,
          "price_per_share": 48.7972
        },
        {
          "date": "2024-11-12",
          "insider": "ZHOU RONG",
          "position": "Officer",
          "type": "Sale",
          "shares": 6893,
          "value": 336930.0,
          "price_per_share": 48.88002321195415
        },
        {
          "date": "2024-11-12",
          "insider": "ZHOU RONG",
          "position": "Officer",
          "type": "Stock Award",
          "shares": 6893,
          "value": 103050.0,
          "price_per_share": 14.949949223850282
        }
      ],
      "summary": {
        "total_sales": 36893,
        "total_purchases": 251410,
        "total_awards": 34393,
        "sales_count": 4,
        "purchases_count": 3,
        "awards_count": 4,
        "total_value": {
          "sales": 1691433.0,
          "purchases": 0.0,
          "awards": 509925.0
        }
      },
      "latest_date": "2024-12-13"
    },
    "recentNews": [
      {
        "title": "JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability",
        "publisher": "Benzinga",
        "timestamp": "2024-09-06T17:46:22Z",
        "url": "https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40754258/jp-morgan-shows-most-interest-in-teva-organon-as-specialty-pharma-sector-exhibits-s",
        "type": "TEVA"
      },
      {
        "title": "HCA Healthcare (HCA) Beats on Q2 Earnings, Ups 2024 EPS View - Zacks Investment Research",
        "publisher": "Zacks Investment Research",
        "timestamp": "2024-07-23T17:01:29Z",
        "url": "https://www.zacks.com/stock/news/2307232/hca-healthcare-hca-beats-on-q2-earnings-ups-2024-eps-view",
        "type": "HCA"
      },
      {
        "title": "Amphastar Pharmaceuticals: Buy When Fear Is Overblown",
        "publisher": "Seeking Alpha",
        "timestamp": "2024-05-30T06:06:15Z",
        "url": "https://seekingalpha.com/article/4696371-amphastar-pharmaceuticals-buy-when-fear-is-overblown",
        "type": "AMPH"
      },
      {
        "title": "Implied Volatility Surging for Amphastar (AMPH) Stock Options",
        "publisher": "Zacks Investment Research",
        "timestamp": "2024-05-15T12:36:00Z",
        "url": "https://www.zacks.com/stock/news/2274065/implied-volatility-surging-for-amphastar-amph-stock-options",
        "type": "AMPH"
      },
      {
        "title": "Amphastar Pharmaceuticals (AMPH) Tops Q1 Earnings and Revenue Estimates",
        "publisher": "Zacks Investment Research",
        "timestamp": "2024-05-08T21:15:08Z",
        "url": "https://www.zacks.com/stock/news/2270879/amphastar-pharmaceuticals-amph-tops-q1-earnings-and-revenue-estimates",
        "type": "AMPH"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": 11.083056,
        "forwardPE": 8.653024
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 2,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": true,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  },
  {
    "symbol": "ANIX",
    "timestamp": "2025-02-04 08:49:52",
    "names": {
      "long": "Anixa Biosciences, Inc.",
      "short": "Anixa Biosciences, Inc.",
      "polygon": "Anixa Biosciences, Inc."
    },
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "description": "Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.",
    "branding": {
      "icon_url": "https://api.polygon.io/v1/reference/company-branding/YW5peGEuY29t/images/2024-10-01_icon.jpeg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq",
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/YW5peGEuY29t/images/2024-10-01_logo.png?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "investing_url": "https://www.investing.com/equities/copytele-inc",
    "price": 2.98,
    "priceChange": 6.428571428571435,
    "openPrice": 3,
    "prevClose": 2.8,
    "dayHigh": 3.05,
    "dayLow": 2.98,
    "volume": 142036,
    "prevVolume": 68654,
    "volumeMetrics": {
      "recentVolumes": [
        97816,
        91010,
        53585,
        68654,
        142036
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        -6.96,
        -41.12,
        28.12,
        106.89
      ],
      "averageVolume": 119492.91666666667,
      "volumeChange": 106.89,
      "volumeVsAvg": 18.87
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 119492.91666666667
    },
    "fiftyTwoWeekHigh": 4.67,
    "fiftyTwoWeekLow": 2.07,
    "highProximityPct": 36.188436830835116,
    "marketCap": 96149488.9906,
    "insiderActivity": {
      "recent_trades": 7,
      "net_shares": 78289,
      "notable_trades": [],
      "summary": {
        "total_sales": 0,
        "total_purchases": 0,
        "total_awards": 78289,
        "sales_count": 0,
        "purchases_count": 0,
        "awards_count": 7,
        "total_value": {
          "sales": 0.0,
          "purchases": 0.0,
          "awards": 186041.0
        }
      },
      "latest_date": "2025-01-28"
    },
    "recentNews": [
      {
        "title": "Anixa Biosciences to Present at the Sidoti Micro-Cap Virtual Conference on November 13 & 14, 2024",
        "publisher": "Benzinga",
        "timestamp": "2024-10-31T12:15:00Z",
        "url": "https://www.benzinga.com/pressreleases/24/10/n41651578/anixa-biosciences-to-present-at-the-sidoti-micro-cap-virtual-conference-on-november-13-14-2024",
        "type": "ANIX"
      },
      {
        "title": "EXCLUSIVE: FDA Approves Anixa Biosciences' Individual Patient Trial Application For Ovarian Cancer CAR-T Therapy - Benzinga",
        "publisher": "Benzinga",
        "timestamp": "2024-07-23T11:45:49Z",
        "url": "https://www.benzinga.com/general/biotech/24/07/39903448/exclusive-fda-approves-anixa-biosciences-individual-patient-trial-application-for-ovarian-cancer-",
        "type": "ANIX"
      },
      {
        "title": "Autonomix secures RF Innovations technology license By Investing.com - Investing.com",
        "publisher": "Investing.com",
        "timestamp": "2024-07-15T16:17:31Z",
        "url": "https://www.investing.com/news/company-news/anixa-biosciences-launches-5-million-stock-buyback-93CH-3519474",
        "type": "ANIX"
      },
      {
        "title": "Dermata (DRMA) Up on FDA Nod to Begin Pivotal Study of Acne Drug",
        "publisher": "Zacks Investment Research",
        "timestamp": "2023-11-17T14:06:00Z",
        "url": "https://www.zacks.com/stock/news/2185908/dermata-drma-up-on-fda-nod-to-begin-pivotal-study-of-acne-drug",
        "type": "LGND"
      },
      {
        "title": "Ardelyx (ARDX) Up on Xphozah's Orphan Tag for Hyperphosphatemia",
        "publisher": "Zacks Investment Research",
        "timestamp": "2023-11-17T14:00:00Z",
        "url": "https://www.zacks.com/stock/news/2185902/ardelyx-ardx-up-on-xphozahs-orphan-tag-for-hyperphosphatemia",
        "type": "LGND"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": null,
        "forwardPE": -8.305555
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 4,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  },
  {
    "symbol": "APVO",
    "timestamp": "2025-02-04 08:49:54",
    "names": {
      "long": "Aptevo Therapeutics Inc.",
      "short": "Aptevo Therapeutics Inc.",
      "polygon": "Aptevo Therapeutics Inc"
    },
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "description": "Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.",
    "branding": {
      "icon_url": null,
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/YXB0ZXZvdGhlcmFwZXV0aWNzLmNvbQ/images/2024-10-01_logo.png?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "investing_url": "https://www.investing.com/equities/aptevo-therapeutics-inc",
    "price": 4.3616,
    "priceChange": 0.26666666666667815,
    "openPrice": 4.36,
    "prevClose": 4.35,
    "dayHigh": 4.4,
    "dayLow": 4.333,
    "volume": 6117,
    "prevVolume": 29261,
    "volumeMetrics": {
      "recentVolumes": [
        32068,
        38419,
        10511,
        29261,
        6117
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        19.8,
        -72.64,
        178.38,
        -79.1
      ],
      "averageVolume": 212129.24279166665,
      "volumeChange": -79.1,
      "volumeVsAvg": -97.12
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 212129.24279166665
    },
    "fiftyTwoWeekHigh": 399.6,
    "fiftyTwoWeekLow": 3.65,
    "highProximityPct": 98.9085085085085,
    "marketCap": 6344227.05,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": [],
      "summary": {
        "total_sales": 0,
        "total_purchases": 0,
        "total_awards": 0,
        "sales_count": 0,
        "purchases_count": 0,
        "awards_count": 0,
        "total_value": {
          "sales": 0,
          "purchases": 0,
          "awards": 0
        }
      },
      "latest_date": null
    },
    "recentNews": [
      {
        "title": "Why Bloom Energy Group Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket - Benzinga",
        "publisher": "Benzinga",
        "timestamp": "2024-07-17T10:03:31Z",
        "url": "https://www.benzinga.com/news/24/07/39810902/why-bloom-energy-group-shares-are-trading-higher-by-12-here-are-20-stocks-moving-premarket",
        "type": "BE"
      },
      {
        "title": "Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E",
        "publisher": "Zacks Investment Research",
        "timestamp": "2024-05-28T12:19:00Z",
        "url": "https://www.zacks.com/stock/news/2279938/why-you-should-bet-on-5-top-ranked-stocks-with-rising-pe",
        "type": "COCO"
      },
      {
        "title": "Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E",
        "publisher": "Zacks Investment Research",
        "timestamp": "2024-04-24T10:31:00Z",
        "url": "https://www.zacks.com/stock/news/2260816/why-you-should-bet-on-5-top-ranked-stocks-with-rising-pe",
        "type": "GRPN"
      },
      {
        "title": "Aptevo (APVO) Stock Plummets 79% in a Week: Here's Why",
        "publisher": "Zacks Investment Research",
        "timestamp": "2024-04-16T16:47:00Z",
        "url": "https://www.zacks.com/stock/news/2256334/aptevo-apvo-stock-plummets-79-in-a-week-heres-why",
        "type": "LGND"
      },
      {
        "title": "Nasdaq Jumps 250 Points; Crude Oil Down 1%",
        "publisher": "Benzinga",
        "timestamp": "2024-04-11T19:21:09Z",
        "url": "https://www.benzinga.com/news/earnings/24/04/38210186/nasdaq-jumps-250-points-crude-oil-down-1",
        "type": "RENT"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": null,
        "forwardPE": -0.29608375
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  },
  {
    "symbol": "ARCT",
    "timestamp": "2025-02-04 08:49:58",
    "names": {
      "long": "Arcturus Therapeutics Holdings Inc.",
      "short": "Arcturus Therapeutics Holdings ",
      "polygon": "Arcturus Therapeutics Holdings Inc. Common Stock"
    },
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "description": "Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.",
    "branding": {
      "icon_url": "https://api.polygon.io/v1/reference/company-branding/YXJjdHVydXNyeC5jb20/images/2024-10-01_icon.jpeg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq",
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/YXJjdHVydXNyeC5jb20/images/2024-10-01_logo.png?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "investing_url": "https://www.investing.com/equities/alcobra-ltd",
    "price": 15.87,
    "priceChange": 0.4430379746835349,
    "openPrice": 15.77,
    "prevClose": 15.8,
    "dayHigh": 16.03,
    "dayLow": 15.34,
    "volume": 99496,
    "prevVolume": 445377,
    "volumeMetrics": {
      "recentVolumes": [
        506409,
        809869,
        355767,
        445377,
        99496
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        59.92,
        -56.07,
        25.19,
        -77.66
      ],
      "averageVolume": 421225.8,
      "volumeChange": -77.66,
      "volumeVsAvg": -76.38
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 421225.8
    },
    "fiftyTwoWeekHigh": 45.0,
    "fiftyTwoWeekLow": 14.3,
    "highProximityPct": 64.73333333333335,
    "marketCap": 421208432.45000005,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": [],
      "summary": {
        "total_sales": 0,
        "total_purchases": 0,
        "total_awards": 0,
        "sales_count": 0,
        "purchases_count": 0,
        "awards_count": 0
      }
    },
    "recentNews": [
      {
        "title": "mRNA Therapeutics Market Size to Hit USD 48.65 Billion by 2032 due to Advances in Cancer Treatment and Expanding mRNA Vaccine Applications | Research by SNS Insider",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-12-08T13:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/12/08/2993373/0/en/mRNA-Therapeutics-Market-Size-to-Hit-USD-48-65-Billion-by-2032-due-to-Advances-in-Cancer-Treatment-and-Expanding-mRNA-Vaccine-Applications-Research-by-SNS-Insider.html",
        "type": "MRNA"
      },
      {
        "title": "mRNA Cancer Vaccines and Therapeutics Research Report 2024 with Long-term Forecasts to 2028 and 2033: Personalized Medicine and Multivalent mRNA Vaccines Lead the Way",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-10-14T15:48:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/10/14/2962732/28124/en/mRNA-Cancer-Vaccines-and-Therapeutics-Research-Report-2024-with-Long-term-Forecasts-to-2028-and-2033-Personalized-Medicine-and-Multivalent-mRNA-Vaccines-Lead-the-Way.html",
        "type": "PFE"
      },
      {
        "title": "Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses",
        "publisher": "Benzinga",
        "timestamp": "2024-09-30T15:12:50Z",
        "url": "https://www.benzinga.com/general/biotech/24/09/41097066/arcturus-therapeuticscsl-partnered-covid-19-vaccine-surpasses-pfizers-comirnaty-shot-even-at-lowe",
        "type": "ARCT"
      },
      {
        "title": "Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma",
        "publisher": "Benzinga",
        "timestamp": "2024-09-13T12:15:00Z",
        "url": "https://www.benzinga.com/pressreleases/24/09/n40852466/japans-ministry-of-health-labor-and-welfare-approves-csl-and-arcturus-therapeutics-updated-self-am",
        "type": "CSLLY"
      },
      {
        "title": "Does Arcturus Therapeutics Have the Potential to Rally 216.35% as Wall Street Analysts Expect?",
        "publisher": "Benzinga",
        "timestamp": "2024-09-03T20:44:51Z",
        "url": "https://www.benzinga.com/news/earnings/24/09/40676136/does-arcturus-therapeutics-have-the-potential-to-rally-216-35-as-wall-street-analysts-expect",
        "type": "ARCT"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": null,
        "forwardPE": -9.106862
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  },
  {
    "symbol": "ARDX",
    "timestamp": "2025-02-04 08:50:00",
    "names": {
      "long": "Ardelyx, Inc.",
      "short": "Ardelyx, Inc.",
      "polygon": "Ardelyx, Inc."
    },
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "description": "Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.",
    "branding": {
      "icon_url": "https://api.polygon.io/v1/reference/company-branding/YXJkZWx5eC5jb20/images/2024-10-01_icon.jpeg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq",
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/YXJkZWx5eC5jb20/images/2024-10-01_logo.svg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "investing_url": "https://www.investing.com/equities/ardelyx-inc",
    "price": 5.41,
    "priceChange": 2.268431001890361,
    "openPrice": 5.29,
    "prevClose": 5.29,
    "dayHigh": 5.48,
    "dayLow": 5.27,
    "volume": 962032,
    "prevVolume": 2023627.0,
    "volumeMetrics": {
      "recentVolumes": [
        2281266.0,
        3596468.0,
        4657702.0,
        2023627.0,
        962032
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        57.65,
        29.51,
        -56.55,
        -52.46
      ],
      "averageVolume": 4811303.8,
      "volumeChange": -52.46,
      "volumeVsAvg": -80.0
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 4811303.8
    },
    "fiftyTwoWeekHigh": 10.13,
    "fiftyTwoWeekLow": 4.32,
    "highProximityPct": 46.59427443237907,
    "marketCap": 1271907429.9,
    "insiderActivity": {
      "recent_trades": 19,
      "net_shares": 1094686,
      "notable_trades": [
        {
          "date": "2025-01-31",
          "insider": "RAAB MICHAEL G",
          "position": "Chief Executive Officer",
          "type": "Stock Award",
          "shares": 41666,
          "value": 223355.0,
          "price_per_share": 5.360605769692315
        },
        {
          "date": "2025-01-21",
          "insider": "MOTT DAVID M",
          "position": "Director",
          "type": "Stock Award",
          "shares": 199000,
          "value": 992672.0,
          "price_per_share": 4.988301507537688
        },
        {
          "date": "2025-01-07",
          "insider": "RAAB MICHAEL G",
          "position": "Chief Executive Officer",
          "type": "Stock Award",
          "shares": 41666,
          "value": 221309.0,
          "price_per_share": 5.311500984015744
        },
        {
          "date": "2024-12-19",
          "insider": "MOTT DAVID M",
          "position": "Director",
          "type": "Stock Award",
          "shares": 213300,
          "value": 996580.0,
          "price_per_share": 4.6721987810595405
        },
        {
          "date": "2024-12-10",
          "insider": "RAAB MICHAEL G",
          "position": "Chief Executive Officer",
          "type": "Stock Award",
          "shares": 25000,
          "value": 131620.0,
          "price_per_share": 5.2648
        },
        {
          "date": "2024-11-25",
          "insider": "RAAB MICHAEL G",
          "position": "Chief Executive Officer",
          "type": "Stock Award",
          "shares": 25000,
          "value": 134482.0,
          "price_per_share": 5.37928
        },
        {
          "date": "2024-11-20",
          "insider": "RAAB MICHAEL G",
          "position": "Chief Executive Officer",
          "type": "Stock Award",
          "shares": 31980,
          "value": 153328.0,
          "price_per_share": 4.794496560350219
        },
        {
          "date": "2024-11-13",
          "insider": "MOTT DAVID M",
          "position": "Director",
          "type": "Stock Award",
          "shares": 215868,
          "value": 996598.0,
          "price_per_share": 4.616700946874942
        }
      ],
      "summary": {
        "total_sales": 0,
        "total_purchases": 0,
        "total_awards": 1094686,
        "sales_count": 0,
        "purchases_count": 0,
        "awards_count": 19,
        "total_value": {
          "sales": 0.0,
          "purchases": 0.0,
          "awards": 4191836.0
        }
      },
      "latest_date": "2025-01-31"
    },
    "recentNews": [
      {
        "title": "Ardelyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2025-01-06T13:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2025/01/06/3004536/0/en/Ardelyx-to-Present-at-the-43rd-Annual-J-P-Morgan-Healthcare-Conference.html",
        "type": "ARDX"
      },
      {
        "title": "Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-11-05T13:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/11/05/2974888/0/en/Ardelyx-to-Participate-at-the-2024-Jefferies-London-Healthcare-Conference.html",
        "type": "ARDX"
      },
      {
        "title": "ARDX DEADLINE TUESDAY: ROSEN, A LEADING LAW FIRM, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important October 15 Deadline in Securities Class Action \u2013 ARDX",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-10-13T11:41:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/10/13/2962272/673/en/ARDX-DEADLINE-TUESDAY-ROSEN-A-LEADING-LAW-FIRM-Encourages-Ardelyx-Inc-Investors-to-Secure-Counsel-Before-Important-October-15-Deadline-in-Securities-Class-Action-ARDX.html",
        "type": "ARDX"
      },
      {
        "title": "SHAREHOLDER ALERT: Holzer & Holzer, LLC Reminds Investors of the October 15, 2024 Lead Plaintiff Deadline in Class Action Lawsuits Filed on Behalf of Symbotic Inc. (SYM), Ardelyx, Inc. (ARDX), PDD Holdings Inc. (PDD), and Sprinklr, Inc. (CXM) Shareholders",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-10-08T21:01:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/10/08/2960161/0/en/SHAREHOLDER-ALERT-Holzer-Holzer-LLC-Reminds-Investors-of-the-October-15-2024-Lead-Plaintiff-Deadline-in-Class-Action-Lawsuits-Filed-on-Behalf-of-Symbotic-Inc-SYM-Ardelyx-Inc-ARDX-P.html",
        "type": "SYM"
      },
      {
        "title": "ROSEN, NATIONAL TRIAL LAWYERS, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important October 15 Deadline in Securities Class Action \u2013 ARDX",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-10-06T11:52:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/10/06/2958589/673/en/ROSEN-NATIONAL-TRIAL-LAWYERS-Encourages-Ardelyx-Inc-Investors-to-Secure-Counsel-Before-Important-October-15-Deadline-in-Securities-Class-Action-ARDX.html",
        "type": "ARDX"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": null,
        "forwardPE": -43.345398
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 2,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": true,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  },
  {
    "symbol": "ARQT",
    "timestamp": "2025-02-04 08:50:03",
    "names": {
      "long": "Arcutis Biotherapeutics, Inc.",
      "short": "Arcutis Biotherapeutics, Inc.",
      "polygon": "Arcutis Biotherapeutics, Inc. Common Stock"
    },
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "description": "Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.",
    "branding": {
      "icon_url": "https://api.polygon.io/v1/reference/company-branding/YXJjdXRpcy5jb20/images/2024-10-01_icon.jpeg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq",
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/YXJjdXRpcy5jb20/images/2024-10-01_logo.svg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "investing_url": "https://www.investing.com/equities/arcutis-biotherapeutics-inc",
    "price": 12.82,
    "priceChange": 1.0244286840031582,
    "openPrice": 12.6,
    "prevClose": 12.69,
    "dayHigh": 12.845,
    "dayLow": 12.09,
    "volume": 699816,
    "prevVolume": 1878761.0,
    "volumeMetrics": {
      "recentVolumes": [
        1390910.0,
        2225048.0,
        1643165.0,
        1878761.0,
        699816
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        59.97,
        -26.15,
        14.34,
        -62.75
      ],
      "averageVolume": 2067698.2333333334,
      "volumeChange": -62.75,
      "volumeVsAvg": -66.15
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 2067698.2333333334
    },
    "fiftyTwoWeekHigh": 16.2,
    "fiftyTwoWeekLow": 5.38,
    "highProximityPct": 20.864197530864192,
    "marketCap": 1434381462.7050002,
    "insiderActivity": {
      "recent_trades": 12,
      "net_shares": 177815,
      "notable_trades": [
        {
          "date": "2025-01-02",
          "insider": "WELGUS HOWARD G",
          "position": "Director",
          "type": "Stock Award",
          "shares": 10000,
          "value": 146714.0,
          "price_per_share": 14.6714
        },
        {
          "date": "2024-12-20",
          "insider": "WATANABE TODD FRANKLIN",
          "position": "Officer and Director",
          "type": "Stock Award",
          "shares": 15000,
          "value": 227566.0,
          "price_per_share": 15.171066666666666
        },
        {
          "date": "2024-12-02",
          "insider": "WELGUS HOWARD G",
          "position": "Director",
          "type": "Stock Award",
          "shares": 10000,
          "value": 125133.0,
          "price_per_share": 12.5133
        },
        {
          "date": "2024-11-22",
          "insider": "BURNETT PATRICK",
          "position": "Officer",
          "type": "Stock Award",
          "shares": 16023,
          "value": 162515.0,
          "price_per_share": 10.142607501716283
        },
        {
          "date": "2024-11-15",
          "insider": "BURNETT PATRICK",
          "position": "Officer",
          "type": "Stock Award",
          "shares": 69226,
          "value": 712621.0,
          "price_per_share": 10.294123595181002
        }
      ],
      "summary": {
        "total_sales": 0,
        "total_purchases": 23352,
        "total_awards": 154463,
        "sales_count": 0,
        "purchases_count": 2,
        "awards_count": 10,
        "total_value": {
          "sales": 0.0,
          "purchases": 0.0,
          "awards": 1627991.0
        }
      },
      "latest_date": "2025-01-02"
    },
    "recentNews": [
      {
        "title": "Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2025-01-12T13:30:00Z",
        "url": "https://www.globenewswire.com/news-release/2025/01/12/3008049/0/en/Arcutis-Announces-Preliminary-Unaudited-Fourth-Quarter-Product-Revenue-and-Full-Year-2024-Product-Revenues-of-Approximately-63-Million-and-160-Million.html",
        "type": "ARQT"
      },
      {
        "title": "Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2025-01-06T21:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2025/01/06/3004950/0/en/Arcutis-Biotherapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html",
        "type": "ARQT"
      },
      {
        "title": "Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-11-06T21:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/11/06/2975996/0/en/Arcutis-Announces-Third-Quarter-2024-Financial-Results-and-Provides-Business-Update.html",
        "type": "ARQT"
      },
      {
        "title": "Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-10-23T20:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/10/23/2968156/0/en/Arcutis-to-Report-Third-Quarter-2024-Financial-Results-and-Participate-in-an-Upcoming-Investor-Conference.html",
        "type": "ARQT"
      },
      {
        "title": "Arcutis (ARQT) Stock Rises 31% in the Past Month: Here's Why - Zacks Investment Research",
        "publisher": "Zacks Investment Research",
        "timestamp": "2024-07-17T14:01:28Z",
        "url": "https://www.zacks.com/stock/news/2303603/arcutis-arqt-stock-rises-31-in-the-past-month-heres-why",
        "type": "ARQT"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": null,
        "forwardPE": -14.937974
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 2,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": true,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  },
  {
    "symbol": "ASMB",
    "timestamp": "2025-02-04 08:50:05",
    "names": {
      "long": "Assembly Biosciences, Inc.",
      "short": "Assembly Biosciences, Inc.",
      "polygon": "Assembly Biosciences, Inc"
    },
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "description": "Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.",
    "branding": {
      "icon_url": "https://api.polygon.io/v1/reference/company-branding/YXNzZW1ibHliaW8uY29t/images/2024-10-01_icon.jpeg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq",
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/YXNzZW1ibHliaW8uY29t/images/2024-10-01_logo.svg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "investing_url": "https://www.investing.com/equities/ventrus-bioscienc",
    "price": 14,
    "priceChange": 1.4492753623188355,
    "openPrice": 13.8,
    "prevClose": 13.8,
    "dayHigh": 14.04,
    "dayLow": 13.6,
    "volume": 7228,
    "prevVolume": 24988,
    "volumeMetrics": {
      "recentVolumes": [
        22897,
        13778,
        14164,
        24988,
        7228
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        -39.83,
        2.8,
        76.42,
        -71.07
      ],
      "averageVolume": 32924.933333333334,
      "volumeChange": -71.07,
      "volumeVsAvg": -78.05
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 32924.933333333334
    },
    "fiftyTwoWeekHigh": 19.93,
    "fiftyTwoWeekLow": 9.84,
    "highProximityPct": 29.75413948820873,
    "marketCap": 87780309.66,
    "insiderActivity": {
      "recent_trades": 4,
      "net_shares": 968741,
      "notable_trades": [
        {
          "date": "2024-12-19",
          "insider": "GILEAD SCIENCES INC",
          "position": "Beneficial Owner of more than 10% of a Class of Security",
          "type": "Stock Award",
          "shares": 940499,
          "value": 14869289.0,
          "price_per_share": 15.809999797979582
        },
        {
          "date": "2024-11-25",
          "insider": "SCHORNSTEIN ALEXANDER",
          "position": "Beneficial Owner of more than 10% of a Class of Security",
          "type": "Stock Award",
          "shares": 25000,
          "value": 371994.0,
          "price_per_share": 14.87976
        }
      ],
      "summary": {
        "total_sales": 0,
        "total_purchases": 0,
        "total_awards": 968741,
        "sales_count": 0,
        "purchases_count": 0,
        "awards_count": 4,
        "total_value": {
          "sales": 0.0,
          "purchases": 0.0,
          "awards": 15291933.0
        }
      },
      "latest_date": "2024-12-30"
    },
    "recentNews": [
      {
        "title": "Insiders Buying American Software And 2 Other Stocks - American Software (NASDAQ:AMSWA) - Benzinga",
        "publisher": "Benzinga",
        "timestamp": "2024-07-09T11:26:13Z",
        "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/07/39684026/insiders-buying-american-software-and-2-other-stocks",
        "type": "AMSWA"
      },
      {
        "title": "Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-06-10T12:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/06/10/2895929/16259/en/Assembly-Biosciences-Doses-First-Participant-in-Phase-1a-b-Clinical-Trial-of-Herpes-Simplex-Virus-Helicase-Primase-Inhibitor-Candidate-ABI-5366.html",
        "type": "ASMB"
      },
      {
        "title": "Are Medical Stocks Lagging  Entera Bio (ENTX) This Year?",
        "publisher": "Zacks Investment Research",
        "timestamp": "2024-05-16T13:40:08Z",
        "url": "https://www.zacks.com/stock/news/2274731/are-medical-stocks-lagging-entera-bio-entx-this-year",
        "type": "ENTX"
      },
      {
        "title": "Are Medical Stocks Lagging  ASLAN Pharmaceuticals (ASLN) This Year?",
        "publisher": "Zacks Investment Research",
        "timestamp": "2024-04-09T13:40:11Z",
        "url": "https://www.zacks.com/stock/news/2252578/are-medical-stocks-lagging-aslan-pharmaceuticals-asln-this-year",
        "type": "ASLN"
      },
      {
        "title": "Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-03-28T20:05:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/03/28/2854455/16259/en/Assembly-Biosciences-Reports-Fourth-Quarter-and-Year-End-2023-Financial-Results-and-Recent-Highlights.html",
        "type": "ASMB"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": null,
        "forwardPE": -1.7434621
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 2,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": true,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  },
  {
    "symbol": "ASRT",
    "timestamp": "2025-02-04 08:50:08",
    "names": {
      "long": "Assertio Holdings, Inc.",
      "short": "Assertio Holdings, Inc.",
      "polygon": "Assertio Holdings, Inc. Common Stock"
    },
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "description": "Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.",
    "branding": {
      "icon_url": "https://api.polygon.io/v1/reference/company-branding/YXNzZXJ0aW90eC5jb20/images/2024-10-01_icon.jpeg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq",
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/YXNzZXJ0aW90eC5jb20/images/2024-10-01_logo.svg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "investing_url": "https://www.investing.com/equities/depomed",
    "price": 0.8109,
    "priceChange": 0.11111111111109886,
    "openPrice": 0.8,
    "prevClose": 0.81,
    "dayHigh": 0.819,
    "dayLow": 0.8,
    "volume": 130503,
    "prevVolume": 307404,
    "volumeMetrics": {
      "recentVolumes": [
        275156,
        354611,
        243308,
        307404,
        130503
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        28.88,
        -31.39,
        26.34,
        -57.55
      ],
      "averageVolume": 780478.15,
      "volumeChange": -57.55,
      "volumeVsAvg": -83.28
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 780478.15
    },
    "fiftyTwoWeekHigh": 1.8,
    "fiftyTwoWeekLow": 0.73,
    "highProximityPct": 54.949999999999996,
    "marketCap": 77317922.44,
    "insiderActivity": {
      "recent_trades": 4,
      "net_shares": 194206,
      "notable_trades": [],
      "summary": {
        "total_sales": 0,
        "total_purchases": 107500,
        "total_awards": 86706,
        "sales_count": 0,
        "purchases_count": 2,
        "awards_count": 2,
        "total_value": {
          "sales": 0.0,
          "purchases": 0.0,
          "awards": 69950.0
        }
      },
      "latest_date": "2025-01-02"
    },
    "recentNews": [
      {
        "title": "Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2025-01-03T21:30:00Z",
        "url": "https://www.globenewswire.com/news-release/2025/01/03/3004175/0/en/Assertio-Holdings-Inc-Reports-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635-c-4.html",
        "type": "ASRT"
      },
      {
        "title": "Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-12-06T12:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/12/06/2992971/0/en/Beam-Therapeutics-Announces-Appointment-of-Sravan-Emany-as-Chief-Financial-Officer.html",
        "type": "BEAM"
      },
      {
        "title": "Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-06-06T20:05:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/06/06/2895049/0/en/Assertio-Holdings-Inc-Reports-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635-c-4.html",
        "type": "ASRT"
      },
      {
        "title": "Assertio to Participate in the Sidoti Small Cap Conference on June 12, 2024",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-06-05T12:30:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/06/05/2893845/0/en/Assertio-to-Participate-in-the-Sidoti-Small-Cap-Conference-on-June-12-2024.html",
        "type": "ASRT"
      },
      {
        "title": "Assertio to Participate in Benchmark Healthcare Conference on May 21-22",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-05-17T13:15:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/05/17/2884261/0/en/Assertio-to-Participate-in-Benchmark-Healthcare-Conference-on-May-21-22.html",
        "type": "ASRT"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": null,
        "forwardPE": 5.18606
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  },
  {
    "symbol": "ATAI",
    "timestamp": "2025-02-04 08:50:10",
    "names": {
      "long": "Atai Life Sciences N.V.",
      "short": "ATAI Life Sciences N.V.",
      "polygon": "ATAI Life Sciences N.V. Common Shares"
    },
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "description": "ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.",
    "branding": {
      "icon_url": "https://api.polygon.io/v1/reference/company-branding/YXRhaS5saWZl/images/2024-10-01_icon.jpeg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq",
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/YXRhaS5saWZl/images/2024-10-01_logo.svg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "investing_url": "https://www.investing.com/equities/atai-life-sciences-bv",
    "price": 2.1601,
    "priceChange": 16.76216216216215,
    "openPrice": 1.86,
    "prevClose": 1.85,
    "dayHigh": 2.235,
    "dayLow": 1.78,
    "volume": 7238268.0,
    "prevVolume": 6767780.0,
    "volumeMetrics": {
      "recentVolumes": [
        1732477.0,
        1361232.0,
        1098377.0,
        6767780.0,
        7238268.0
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        -21.43,
        -19.31,
        516.16,
        6.95
      ],
      "averageVolume": 2030741.8833333333,
      "volumeChange": 6.95,
      "volumeVsAvg": 256.43
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 2030741.8833333333
    },
    "fiftyTwoWeekHigh": 2.85,
    "fiftyTwoWeekLow": 1.03,
    "highProximityPct": 24.207017543859656,
    "marketCap": 317985540.42,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": [],
      "summary": {
        "total_sales": 0,
        "total_purchases": 0,
        "total_awards": 0,
        "sales_count": 0,
        "purchases_count": 0,
        "awards_count": 0
      }
    },
    "recentNews": [
      {
        "title": "5-HT2 Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2025-01-22T18:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2025/01/22/3013790/0/en/5-HT2-Agonist-Clinical-Trial-Pipeline-Appears-Robust-With-20-Key-Pharma-Companies-Actively-Working-in-the-Therapeutics-Segment-DelveInsight.html",
        "type": "CYBN"
      },
      {
        "title": "4 Psychedelic Stocks to Consider as Clinical Trials Heat up",
        "publisher": "Investing.com",
        "timestamp": "2024-08-06T19:13:00Z",
        "url": "https://www.investing.com/analysis/4-psychedelic-stocks-to-consider-as-clinical-trials-heat-up-200650705",
        "type": "ATAI"
      },
      {
        "title": "atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-06-26T11:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/06/26/2904391/0/en/atai-Life-Sciences-to-Participate-in-the-H-C-Wainwright-5th-Annual-Neuro-Perspectives-Conference.html",
        "type": "ATAI"
      },
      {
        "title": "atai Life Sciences Announces Update on Beckley Psytech\u2019s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-06-20T11:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/06/20/2901566/0/en/atai-Life-Sciences-Announces-Update-on-Beckley-Psytech-s-Phase-1-2a-Trial-of-ELE-101-IV-Psilocin-for-Major-Depressive-Disorder-with-Initial-Results-from-Phase-1-and-First-Patients-.html",
        "type": "ATAI"
      },
      {
        "title": "Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment",
        "publisher": "Benzinga",
        "timestamp": "2024-06-05T19:26:42Z",
        "url": "https://www.benzinga.com/markets/psychedelics/24/06/39192640/psychedelic-stocks-trip-up-after-fda-advisors-reject-mdma-for-ptsd-treatment",
        "type": "ATAI"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": null,
        "forwardPE": -3.214122
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 2,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  },
  {
    "symbol": "AUPH",
    "timestamp": "2025-02-04 08:50:13",
    "names": {
      "long": "Aurinia Pharmaceuticals Inc.",
      "short": "Aurinia Pharmaceuticals Inc",
      "polygon": "Aurinia Pharmaceuticals Inc"
    },
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "description": "Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.",
    "branding": {
      "icon_url": "https://api.polygon.io/v1/reference/company-branding/YXVyaW5pYXBoYXJtYS5jb20/images/2024-10-01_icon.png?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq",
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/YXVyaW5pYXBoYXJtYS5jb20/images/2024-10-01_logo.png?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "investing_url": "https://www.investing.com/equities/aurinia-pharmace",
    "price": 7.895,
    "priceChange": 1.0883482714468626,
    "openPrice": 7.81,
    "prevClose": 7.81,
    "dayHigh": 7.95,
    "dayLow": 7.78,
    "volume": 271450,
    "prevVolume": 1130018.0,
    "volumeMetrics": {
      "recentVolumes": [
        850216,
        956458,
        1099293.0,
        1130018.0,
        271450
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        12.5,
        14.93,
        2.79,
        -75.98
      ],
      "averageVolume": 1428419.3166666667,
      "volumeChange": -75.98,
      "volumeVsAvg": -81.0
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 1428419.3166666667
    },
    "fiftyTwoWeekHigh": 10.67,
    "fiftyTwoWeekLow": 4.71,
    "highProximityPct": 26.0074976569822,
    "marketCap": 1122525468.96,
    "insiderActivity": {
      "recent_trades": 10,
      "net_shares": 1314795,
      "notable_trades": [
        {
          "date": "2024-12-09",
          "insider": "TANG KEVIN C",
          "position": "Director",
          "type": "Stock Award",
          "shares": 1200000,
          "value": 10822000.0,
          "price_per_share": 9.018333333333333
        }
      ],
      "summary": {
        "total_sales": 0,
        "total_purchases": 104997,
        "total_awards": 1209798,
        "sales_count": 0,
        "purchases_count": 7,
        "awards_count": 3,
        "total_value": {
          "sales": 0.0,
          "purchases": 0.0,
          "awards": 10904598.0
        }
      },
      "latest_date": "2024-12-09"
    },
    "recentNews": [
      {
        "title": "New American College of Rheumatology Guidelines for Lupus Nephritis Recommend Triple Therapy, Highlighting a Shift in Current Treatment Practices, According to Spherix Global Insights",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2025-01-08T20:35:00Z",
        "url": "https://www.globenewswire.com/news-release/2025/01/08/3006644/0/en/New-American-College-of-Rheumatology-Guidelines-for-Lupus-Nephritis-Recommend-Triple-Therapy-Highlighting-a-Shift-in-Current-Treatment-Practices-According-to-Spherix-Global-Insight.html",
        "type": "GSK"
      },
      {
        "title": "Corporate and Individual Donations Provide Much-Needed Support to Kidney Patients Impacted by Hurricane Helene Through the American Kidney Fund\u2019s Disaster Relief Program",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-10-02T13:48:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/10/02/2957056/0/en/Corporate-and-Individual-Donations-Provide-Much-Needed-Support-to-Kidney-Patients-Impacted-by-Hurricane-Helene-Through-the-American-Kidney-Fund-s-Disaster-Relief-Program.html",
        "type": "AUPH"
      },
      {
        "title": "Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump Turn into More Strength?",
        "publisher": "Zacks Investment Research",
        "timestamp": "2024-06-17T08:46:00Z",
        "url": "https://www.zacks.com/stock/news/2288862/strength-seen-in-aurinia-auph-can-its-56-jump-turn-into-more-strength",
        "type": "AUPH"
      },
      {
        "title": "How Much Upside is Left in Aurinia (AUPH)? Wall Street Analysts Think 96.51%",
        "publisher": "Zacks Investment Research",
        "timestamp": "2024-05-07T13:55:11Z",
        "url": "https://www.zacks.com/stock/news/2269684/how-much-upside-is-left-in-aurinia-auph-wall-street-analysts-think-9651",
        "type": "AUPH"
      },
      {
        "title": "Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates",
        "publisher": "Zacks Investment Research",
        "timestamp": "2024-05-02T11:10:09Z",
        "url": "https://www.zacks.com/stock/news/2266638/aurinia-pharmaceuticals-auph-reports-q1-loss-tops-revenue-estimates",
        "type": "AUPH"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": null,
        "forwardPE": 13.800698
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 2,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": true,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  },
  {
    "symbol": "AXSM",
    "timestamp": "2025-02-04 08:50:16",
    "names": {
      "long": "Axsome Therapeutics, Inc.",
      "short": "Axsome Therapeutics, Inc.",
      "polygon": "Axsome Therapeutics, Inc"
    },
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "description": "Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.",
    "branding": {
      "icon_url": "https://api.polygon.io/v1/reference/company-branding/YXhzb21lLmNvbQ/images/2024-10-01_icon.jpeg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq",
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/YXhzb21lLmNvbQ/images/2024-10-01_logo.png?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "investing_url": "https://www.investing.com/equities/axsome-therapeutics-inc",
    "price": 110.975,
    "priceChange": 3.2998231406497136,
    "openPrice": 108.52,
    "prevClose": 107.43,
    "dayHigh": 111.82,
    "dayLow": 107.995,
    "volume": 198455,
    "prevVolume": 933473,
    "volumeMetrics": {
      "recentVolumes": [
        692957,
        1193348.0,
        987631,
        933473,
        198455
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        72.21,
        -17.24,
        -5.48,
        -78.74
      ],
      "averageVolume": 748172.1166666667,
      "volumeChange": -78.74,
      "volumeVsAvg": -73.47
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 748172.1166666667
    },
    "fiftyTwoWeekHigh": 111.7604,
    "fiftyTwoWeekLow": 64.11,
    "highProximityPct": 0.7027533902885188,
    "marketCap": 5290498424.9549,
    "insiderActivity": {
      "recent_trades": 2,
      "net_shares": 42537,
      "notable_trades": [
        {
          "date": "2024-11-19",
          "insider": "COLEMAN MARK H",
          "position": "Director",
          "type": "Stock Award",
          "shares": 33410,
          "value": 198455.0,
          "price_per_share": 5.939988027536666
        }
      ],
      "summary": {
        "total_sales": 0,
        "total_purchases": 0,
        "total_awards": 42537,
        "sales_count": 0,
        "purchases_count": 0,
        "awards_count": 2,
        "total_value": {
          "sales": 0.0,
          "purchases": 0.0,
          "awards": 280598.0
        }
      },
      "latest_date": "2025-01-03"
    },
    "recentNews": [
      {
        "title": "Axsome Therapeutics Hosts SYMBRAVO\u00ae FDA Approval Virtual Investor Event with Expert Thought Leader",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2025-01-31T12:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2025/01/31/3018708/33090/en/Axsome-Therapeutics-Hosts-SYMBRAVO-FDA-Approval-Virtual-Investor-Event-with-Expert-Thought-Leader.html",
        "type": "AXSM"
      },
      {
        "title": "Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer\u2019s Disease Agitation",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-12-30T12:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/12/30/3002588/33090/en/Axsome-Therapeutics-Announces-Successful-Completion-and-Results-of-Phase-3-Clinical-Program-of-AXS-05-in-Alzheimer-s-Disease-Agitation.html",
        "type": "AXSM"
      },
      {
        "title": "Is It Too Late to Buy Viking Therapeutics Stock?",
        "publisher": "The Motley Fool",
        "timestamp": "2024-11-17T12:05:00Z",
        "url": "https://www.fool.com/investing/2024/11/17/is-it-too-late-to-buy-viking-therapeutics-stock/?source=iedfolrf0000001",
        "type": "VKTX"
      },
      {
        "title": "3 Bargain Stocks to Buy in a Market That's Priced for Perfection",
        "publisher": "The Motley Fool",
        "timestamp": "2024-10-19T11:30:00Z",
        "url": "https://www.fool.com/investing/2024/10/19/3-bargain-stocks-to-buy-in-a-market-thats-priced-f/?source=iedfolrf0000001",
        "type": "AXSM"
      },
      {
        "title": "1 Under-the-Radar Biotech Stock to Buy and Hold",
        "publisher": "The Motley Fool",
        "timestamp": "2024-09-29T11:32:00Z",
        "url": "https://www.fool.com/investing/2024/09/29/1-under-the-radar-biotech-stock-to-buy-and-hold/?source=iedfolrf0000001",
        "type": "AXSM"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": null,
        "forwardPE": -62.456627
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": true,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": true
    }
  },
  {
    "symbol": "BCRX",
    "timestamp": "2025-02-04 08:50:19",
    "names": {
      "long": "BioCryst Pharmaceuticals, Inc.",
      "short": "BioCryst Pharmaceuticals, Inc.",
      "polygon": "BioCryst Pharmaceuticals Inc"
    },
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "description": "BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block\u00a0key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.",
    "branding": {
      "icon_url": "https://api.polygon.io/v1/reference/company-branding/YmlvY3J5c3QuY29t/images/2024-10-01_icon.jpeg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq",
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/YmlvY3J5c3QuY29t/images/2024-10-01_logo.png?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "investing_url": "https://www.investing.com/equities/biocryst-pharmaceuticals",
    "price": 7.98,
    "priceChange": 4.724409448818902,
    "openPrice": 7.59,
    "prevClose": 7.62,
    "dayHigh": 8.02,
    "dayLow": 7.57,
    "volume": 630072,
    "prevVolume": 2151753.0,
    "volumeMetrics": {
      "recentVolumes": [
        1813397.0,
        2217510.0,
        1803083.0,
        2151753.0,
        630072
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        22.28,
        -18.69,
        19.34,
        -70.72
      ],
      "averageVolume": 2003725.3333333333,
      "volumeChange": -70.72,
      "volumeVsAvg": -68.55
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 2003725.3333333333
    },
    "fiftyTwoWeekHigh": 8.88,
    "fiftyTwoWeekLow": 4.03,
    "highProximityPct": 10.135135135135139,
    "marketCap": 1621848030.93,
    "insiderActivity": {
      "recent_trades": 8,
      "net_shares": 883150,
      "notable_trades": [],
      "summary": {
        "total_sales": 0,
        "total_purchases": 875400,
        "total_awards": 7750,
        "sales_count": 0,
        "purchases_count": 6,
        "awards_count": 2,
        "total_value": {
          "sales": 0.0,
          "purchases": 0.0,
          "awards": 58405.0
        }
      },
      "latest_date": "2024-12-20"
    },
    "recentNews": [
      {
        "title": "BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2025-01-07T12:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2025/01/07/3005246/29446/en/BioCryst-to-Present-at-43rd-Annual-J-P-Morgan-Healthcare-Conference.html",
        "type": "BCRX"
      },
      {
        "title": "BioCryst to Present at Upcoming Investor Conferences",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-11-06T12:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/11/06/2975588/29446/en/BioCryst-to-Present-at-Upcoming-Investor-Conferences.html",
        "type": "BCRX"
      },
      {
        "title": "BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-11-05T12:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/11/05/2974802/29446/en/BioCryst-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html",
        "type": "BCRX"
      },
      {
        "title": "U.S. Government Awards BioCryst $69 Million RAPIVAB\u00ae (peramivir injection) Contract for Strategic National Stockpile",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-09-30T11:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/09/30/2955050/29446/en/U-S-Government-Awards-BioCryst-69-Million-RAPIVAB-peramivir-injection-Contract-for-Strategic-National-Stockpile.html",
        "type": "BCRX"
      },
      {
        "title": "BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO\u00ae (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema Attacks",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-09-17T11:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/09/17/2947276/29446/en/BioCryst-and-the-pan-Canadian-Pharmaceutical-Alliance-pCPA-Successfully-Complete-Negotiations-for-ORLADEYO-berotralstat-an-Oral-Once-daily-Therapy-for-the-Prevention-of-Hereditary-.html",
        "type": "BCRX"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": null,
        "forwardPE": -125.36325
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  },
  {
    "symbol": "BHC",
    "timestamp": "2025-02-04 08:50:21",
    "names": {
      "long": "Bausch Health Companies Inc.",
      "short": "Bausch Health Companies Inc.",
      "polygon": "Bausch\u00a0Health\u00a0Companies\u00a0Inc."
    },
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "description": "Bausch Health Companies Inc is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.",
    "branding": {
      "icon_url": "https://api.polygon.io/v1/reference/company-branding/YmF1c2NoaGVhbHRoLmNvbQ/images/2024-10-01_icon.jpeg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq",
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/YmF1c2NoaGVhbHRoLmNvbQ/images/2024-10-01_logo.svg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "investing_url": "https://www.investing.com/equities/valeant-pharma",
    "price": 7.35,
    "priceChange": 0.9615384615384532,
    "openPrice": 7.24,
    "prevClose": 7.28,
    "dayHigh": 7.37,
    "dayLow": 7.2,
    "volume": 242644,
    "prevVolume": 6093512.0,
    "volumeMetrics": {
      "recentVolumes": [
        1479032.0,
        8103284.0,
        1423210.0,
        6093512.0,
        242644
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        447.88,
        -82.44,
        328.15,
        -96.02
      ],
      "averageVolume": 1858726.3166666667,
      "volumeChange": -96.02,
      "volumeVsAvg": -86.95
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 1858726.3166666667
    },
    "fiftyTwoWeekHigh": 11.46,
    "fiftyTwoWeekLow": 3.96,
    "highProximityPct": 35.863874345549746,
    "marketCap": 2673930725.27,
    "insiderActivity": {
      "recent_trades": 4,
      "net_shares": 13155,
      "notable_trades": [],
      "summary": {
        "total_sales": 0,
        "total_purchases": 0,
        "total_awards": 13155,
        "sales_count": 0,
        "purchases_count": 0,
        "awards_count": 4,
        "total_value": {
          "sales": 0.0,
          "purchases": 0.0,
          "awards": 106157.0
        }
      },
      "latest_date": "2024-12-31"
    },
    "recentNews": [
      {
        "title": "George Medicines signs exclusive licensing agreement with Bausch Health to commercialize GMRx2 in Canada, Mexico, Columbia and Central America",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2025-01-13T12:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2025/01/13/3008286/0/en/George-Medicines-signs-exclusive-licensing-agreement-with-Bausch-Health-to-commercialize-GMRx2-in-Canada-Mexico-Columbia-and-Central-America.html",
        "type": "BHC"
      },
      {
        "title": "2024 Research | Europe Retinal Surgery Devices Market Poised for Growth, Expected to Reach $1.16 Billion by 2032, Driven by Rising Prevalence of Retinal Diseases and Technological Advancements",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-10-23T14:47:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/10/23/2967983/28124/en/2024-Research-Europe-Retinal-Surgery-Devices-Market-Poised-for-Growth-Expected-to-Reach-1-16-Billion-by-2032-Driven-by-Rising-Prevalence-of-Retinal-Diseases-and-Technological-Advan.html",
        "type": "ALC"
      },
      {
        "title": "Non-Invasive Aesthetic Treatment Industry Report 2024, Featuring Profiles of Alma Lasers, Bausch Health Companies, Candela, Cutera, Cynosure Lutronic, Daeyang Medical, Fotona, Galderma and More",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-10-21T14:46:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/10/21/2966334/28124/en/Non-Invasive-Aesthetic-Treatment-Industry-Report-2024-Featuring-Profiles-of-Alma-Lasers-Bausch-Health-Companies-Candela-Cutera-Cynosure-Lutronic-Daeyang-Medical-Fotona-Galderma-and.html",
        "type": "BHC"
      },
      {
        "title": "Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?",
        "publisher": "Benzinga",
        "timestamp": "2024-09-22T21:34:03Z",
        "url": "https://www.benzinga.com/news/mid-cap/24/09/40972110/bausch-lomb-and-edgewise-therapeutics-are-among-top-7-mid-cap-stock-gainers-last-week-sept-15-sept-2",
        "type": "EWTX"
      },
      {
        "title": "Chemotherapy Induced Nausea and Vomiting Treatment Market is Set to Reach US$ 12,688.0 Million by 2034 | Fact.MR",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-09-17T10:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/09/17/2947224/0/en/Chemotherapy-Induced-Nausea-and-Vomiting-Treatment-Market-is-Set-to-Reach-US-12-688-0-Million-by-2034-Fact-MR.html",
        "type": "PFE"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": null,
        "forwardPE": 1.7028606
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  },
  {
    "symbol": "BIIB",
    "timestamp": "2025-02-04 08:50:23",
    "names": {
      "long": "Biogen Inc.",
      "short": "Biogen Inc.",
      "polygon": "Biogen Inc. Common Stock"
    },
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "description": "Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.",
    "branding": {
      "icon_url": "https://api.polygon.io/v1/reference/company-branding/YmlvZ2VuLmNvbQ/images/2024-10-01_icon.jpeg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq",
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/YmlvZ2VuLmNvbQ/images/2024-10-01_logo.svg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "investing_url": "https://www.investing.com/equities/biogen-idec-inc",
    "price": 143.37,
    "priceChange": 0.7236195025994107,
    "openPrice": 141.08,
    "prevClose": 142.34,
    "dayHigh": 143.7099,
    "dayLow": 141.07,
    "volume": 380433,
    "prevVolume": 1028984.0,
    "volumeMetrics": {
      "recentVolumes": [
        1367096.0,
        1078979.0,
        1376249.0,
        1028984.0,
        380433
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        -21.08,
        27.55,
        -25.23,
        -63.03
      ],
      "averageVolume": 1397915.5166666666,
      "volumeChange": -63.03,
      "volumeVsAvg": -72.79
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 1397915.5166666666
    },
    "fiftyTwoWeekHigh": 246.44,
    "fiftyTwoWeekLow": 139.71,
    "highProximityPct": 41.8235676026619,
    "marketCap": 20716189971.1,
    "insiderActivity": {
      "recent_trades": 4,
      "net_shares": 2495,
      "notable_trades": [],
      "summary": {
        "total_sales": 110,
        "total_purchases": 2605,
        "total_awards": 0,
        "sales_count": 1,
        "purchases_count": 3,
        "awards_count": 0,
        "total_value": {
          "sales": 17293.0,
          "purchases": 0.0,
          "awards": 0.0
        }
      },
      "latest_date": "2025-01-31"
    },
    "recentNews": [
      {
        "title": "Orphan Designated Drugs Market Analysis: Key Trends, Players and Forecasts for Future Growth",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2025-02-03T09:52:00Z",
        "url": "https://www.globenewswire.com/news-release/2025/02/03/3019270/28124/en/Orphan-Designated-Drugs-Market-Analysis-Key-Trends-Players-and-Forecasts-for-Future-Growth.html",
        "type": "ABBV"
      },
      {
        "title": "Deal Dispatch: Sage And Silvus Are Up For Sale, MrBeast Secures $20B For TikTok",
        "publisher": "Benzinga",
        "timestamp": "2025-01-31T19:20:27Z",
        "url": "https://www.benzinga.com/news/global/25/01/43402048/deal-dispatch-sage-and-silvus-are-up-for-sale-mrbeast-secures-20b-for-tiktok",
        "type": "ALLK"
      },
      {
        "title": "Recombinant Chemicals Market to Reach US$ 6.7 Bn by 2034, Driven by Rising Demand for Protein-Based Vaccines & Genetic Disorder Treatments \u2013 TMR Analysis",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2025-01-31T14:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2025/01/31/3018829/32656/en/Recombinant-Chemicals-Market-to-Reach-US-6-7-Bn-by-2034-Driven-by-Rising-Demand-for-Protein-Based-Vaccines-Genetic-Disorder-Treatments-TMR-Analysis.html",
        "type": "AMGN"
      },
      {
        "title": "Biological Drugs Strategic Research Report 2024-2030, Profiles of 45+ Players Including Abbott Laboratories, Amgen, Baxter, Biogen, BMS, Eli Lilly and Co, GSK, Merck, Novartis, and Pfizer",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2025-01-27T15:49:00Z",
        "url": "https://www.globenewswire.com/news-release/2025/01/27/3015778/28124/en/Biological-Drugs-Strategic-Research-Report-2024-2030-Profiles-of-45-Players-Including-Abbott-Laboratories-Amgen-Baxter-Biogen-BMS-Eli-Lilly-and-Co-GSK-Merck-Novartis-and-Pfizer.html",
        "type": "ABT"
      },
      {
        "title": "FDA Approves LEQEMBI\u00ae (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer\u2019s Disease",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2025-01-26T23:33:00Z",
        "url": "https://www.globenewswire.com/news-release/2025/01/26/3015260/0/en/FDA-Approves-LEQEMBI-lecanemab-irmb-IV-Maintenance-Dosing-for-the-Treatment-of-Early-Alzheimer-s-Disease.html",
        "type": "BIIB"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": 12.97466,
        "forwardPE": 8.807452
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  },
  {
    "symbol": "BNGO",
    "timestamp": "2025-02-04 08:50:26",
    "names": {
      "long": "Bionano Genomics, Inc.",
      "short": "Bionano Genomics, Inc.",
      "polygon": "Bionano Genomics, Inc. Common Stock"
    },
    "sector": "Healthcare",
    "industry": "Medical Instruments & Supplies",
    "description": "Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas. They generate product revenue from sales of its OGM and Ionic Purification systems and consumables, which includes its instruments, and their VIA software.",
    "branding": {
      "icon_url": "https://api.polygon.io/v1/reference/company-branding/YmlvbmFuby5jb20/images/2024-10-01_icon.jpeg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq",
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/YmlvbmFuby5jb20/images/2024-10-01_logo.svg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "investing_url": "https://www.investing.com/equities/bionano-genomics",
    "price": 4.96,
    "priceChange": -6.415094339622638,
    "openPrice": 5.3,
    "prevClose": 5.3,
    "dayHigh": 5.33,
    "dayLow": 4.91,
    "volume": 157311,
    "prevVolume": 234558,
    "volumeMetrics": {
      "recentVolumes": [
        479569,
        386924,
        233718,
        234558,
        157311
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        -19.32,
        -39.6,
        0.36,
        -32.93
      ],
      "averageVolume": 181654.68917333335,
      "volumeChange": -32.93,
      "volumeVsAvg": -13.4
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 181654.68917333335
    },
    "fiftyTwoWeekHigh": 81.0,
    "fiftyTwoWeekLow": 4.75,
    "highProximityPct": 93.87654320987654,
    "marketCap": 12233455.798,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": [],
      "summary": {
        "total_sales": 0,
        "total_purchases": 0,
        "total_awards": 0,
        "sales_count": 0,
        "purchases_count": 0,
        "awards_count": 0
      }
    },
    "recentNews": [
      {
        "title": "Bionano Announces $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2025-01-03T19:34:00Z",
        "url": "https://www.globenewswire.com/news-release/2025/01/03/3004131/0/en/Bionano-Announces-10-Million-Registered-Direct-Offering-Priced-At-the-Market-under-Nasdaq-Rules.html",
        "type": "BNGO"
      },
      {
        "title": "Bionano Announces Amendment to Senior Secured Convertible Debentures in Debt Restructuring that Improves Cash Runway",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-12-31T20:26:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/12/31/3003198/0/en/Bionano-Announces-Amendment-to-Senior-Secured-Convertible-Debentures-in-Debt-Restructuring-that-Improves-Cash-Runway.html",
        "type": "BNGO"
      },
      {
        "title": "Bionano Announces Preliminary 3Q 2024 Revenues and Cash",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-10-10T12:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/10/10/2961238/0/en/Bionano-Announces-Preliminary-3Q-2024-Revenues-and-Cash.html",
        "type": "BNGO"
      },
      {
        "title": "10 Consumer Discretionary Stocks With Whale Alerts In Today's Session - Benzinga",
        "publisher": "Benzinga",
        "timestamp": "2024-07-17T17:35:17Z",
        "url": "https://www.benzinga.com/insights/options/24/07/39822451/10-consumer-discretionary-stocks-with-whale-alerts-in-todays-session",
        "type": "TSLA"
      },
      {
        "title": "Bionano Genomics (BNGO) Q1 2024 Earnings Call Transcript",
        "publisher": "The Motley Fool",
        "timestamp": "2024-05-08T22:30:14Z",
        "url": "https://www.fool.com/earnings/call-transcripts/2024/05/08/bionano-genomics-bngo-q1-2024-earnings-call-transc/",
        "type": "BNGO"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": null,
        "forwardPE": -0.17048647
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 2,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  },
  {
    "symbol": "CDTX",
    "timestamp": "2025-02-04 08:50:29",
    "names": {
      "long": "Cidara Therapeutics, Inc.",
      "short": "Cidara Therapeutics, Inc.",
      "polygon": "Cidara Therapeutics, Inc."
    },
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "description": "Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.",
    "branding": {
      "icon_url": "https://api.polygon.io/v1/reference/company-branding/Y2lkYXJhLmNvbQ/images/2024-10-01_icon.jpeg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq",
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/Y2lkYXJhLmNvbQ/images/2024-10-01_logo.svg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "investing_url": "https://www.investing.com/equities/cidara-therapeutics-inc",
    "price": 19.29,
    "priceChange": 1.79419525065963,
    "openPrice": 18.87,
    "prevClose": 18.95,
    "dayHigh": 19.65,
    "dayLow": 18.755,
    "volume": 42149,
    "prevVolume": 134306,
    "volumeMetrics": {
      "recentVolumes": [
        31708,
        72545,
        77170,
        134306,
        42149
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        128.79,
        6.38,
        74.04,
        -68.62
      ],
      "averageVolume": 89704.58333333333,
      "volumeChange": -68.62,
      "volumeVsAvg": -53.01
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 89704.58333333333
    },
    "fiftyTwoWeekHigh": 28.42,
    "fiftyTwoWeekLow": 10.0,
    "highProximityPct": 32.12526389866292,
    "marketCap": 210531595.225,
    "insiderActivity": {
      "recent_trades": 1,
      "net_shares": 389716,
      "notable_trades": [
        {
          "date": "2024-11-26",
          "insider": "RA CAPITAL MANAGEMENT, L.P.",
          "position": "Director",
          "type": "Stock Award",
          "shares": 389716,
          "value": 7634536.0,
          "price_per_share": 19.589998870972707
        }
      ],
      "summary": {
        "total_sales": 0,
        "total_purchases": 0,
        "total_awards": 389716,
        "sales_count": 0,
        "purchases_count": 0,
        "awards_count": 1,
        "total_value": {
          "sales": 0.0,
          "purchases": 0.0,
          "awards": 7634536.0
        }
      },
      "latest_date": "2024-11-26"
    },
    "recentNews": [
      {
        "title": "Cidara Therapeutics to Participate in Evercore 7th Annual HealthCONx Conference",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-11-19T13:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/11/19/2983510/0/en/Cidara-Therapeutics-to-Participate-in-Evercore-7th-Annual-HealthCONx-Conference.html",
        "type": "CDTX"
      },
      {
        "title": "Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-10-04T20:30:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/10/04/2958516/0/en/Cidara-Therapeutics-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-C-4.html",
        "type": "CDTX"
      },
      {
        "title": "Cidara Therapeutics Announces Two Presentations on Innovative Drug-Fc Conjugate, CD388, at the 2024 OPTIONS XII for the Control of Influenza Conference",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-09-25T12:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/09/25/2952884/0/en/Cidara-Therapeutics-Announces-Two-Presentations-on-Innovative-Drug-Fc-Conjugate-CD388-at-the-2024-OPTIONS-XII-for-the-Control-of-Influenza-Conference.html",
        "type": "CDTX"
      },
      {
        "title": "Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-09-23T12:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/09/23/2951361/0/en/Cidara-Therapeutics-Announces-First-Subjects-Dosed-in-Phase-2b-NAVIGATE-Trial-Evaluating-CD388-for-the-Prevention-of-Seasonal-Influenza.html",
        "type": "CDTX"
      },
      {
        "title": "Cidara Therapeutics Strengthens its Scientific Advisory Board with Infectious Disease Experts",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-09-19T12:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/09/19/2948932/0/en/Cidara-Therapeutics-Strengthens-its-Scientific-Advisory-Board-with-Infectious-Disease-Experts.html",
        "type": "CDTX"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": null,
        "forwardPE": -2.2605653
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 2,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": true,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  },
  {
    "symbol": "CLOV",
    "timestamp": "2025-02-04 08:50:31",
    "names": {
      "long": "Clover Health Investments, Corp.",
      "short": "Clover Health Investments, Corp",
      "polygon": "Clover Health Investments, Corp"
    },
    "sector": "Healthcare",
    "industry": "Healthcare Plans",
    "description": "Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. Operating in two segments, Insurance and Non-Insurance, Clover Health offers PPO and HMO plans to Medicare Advantage members in multiple states through its Insurance segment. In the Non-Insurance segment, the company participates in the ACO REACH Model. The majority of revenue is generated from the insurance segment, reflecting the significance of its healthcare insurance offerings.",
    "branding": {
      "icon_url": "https://api.polygon.io/v1/reference/company-branding/Y2xvdmVyaGVhbHRoLmNvbQ/images/2024-10-01_icon.jpeg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq",
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/Y2xvdmVyaGVhbHRoLmNvbQ/images/2024-10-01_logo.svg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "investing_url": "https://www.investing.com/equities/social-capital-hedosophia-hold-iii",
    "price": 4.4572,
    "priceChange": 3.4153132250580205,
    "openPrice": 4.31,
    "prevClose": 4.31,
    "dayHigh": 4.46,
    "dayLow": 4.29,
    "volume": 1755437.0,
    "prevVolume": 6552416.0,
    "volumeMetrics": {
      "recentVolumes": [
        5448952.0,
        4571282.0,
        4811537.0,
        6552416.0,
        1755437.0
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        -16.11,
        5.26,
        36.18,
        -73.21
      ],
      "averageVolume": 6162918.283333333,
      "volumeChange": -73.21,
      "volumeVsAvg": -71.52
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 6162918.283333333
    },
    "fiftyTwoWeekHigh": 4.87,
    "fiftyTwoWeekLow": 0.606,
    "highProximityPct": 8.476386036960983,
    "marketCap": 2199868668.04,
    "insiderActivity": {
      "recent_trades": 8,
      "net_shares": 2097790,
      "notable_trades": [],
      "summary": {
        "total_sales": 0,
        "total_purchases": 2097790,
        "total_awards": 0,
        "sales_count": 0,
        "purchases_count": 8,
        "awards_count": 0,
        "total_value": {
          "sales": 0.0,
          "purchases": 0.0,
          "awards": 0.0
        }
      },
      "latest_date": "2025-01-07"
    },
    "recentNews": [
      {
        "title": "Hindenburg Research Issued a Scathing Short Report on Super Micro Computer. This Is What Happened to 3 Other Big Stocks It Targeted.",
        "publisher": "The Motley Fool",
        "timestamp": "2024-09-10T17:51:00Z",
        "url": "https://www.fool.com/investing/2024/09/10/hindenburg-research-issued-a-scathing-short-report/?source=iedfolrf0000001",
        "type": "CLOV"
      },
      {
        "title": "Clover Health Regains Compliance with NASDAQ Minimum Bid Price Requirement",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-06-26T20:15:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/06/26/2904822/0/en/Clover-Health-Regains-Compliance-with-NASDAQ-Minimum-Bid-Price-Requirement.html",
        "type": "CLOV"
      },
      {
        "title": "Clover Health Stock Is Surging After The Close: What's Going On?",
        "publisher": "Benzinga",
        "timestamp": "2024-06-20T20:37:05Z",
        "url": "https://www.benzinga.com/news/24/06/39422607/clover-health-stock-is-surging-after-the-close-whats-going-on",
        "type": "CLOV"
      },
      {
        "title": "CMS Improves Star Ratings to 3.5 Stars for Clover Health PPO Medicare Advantage Plans for 2025 Payment Year",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-06-14T13:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/06/14/2898994/0/en/CMS-Improves-Star-Ratings-to-3-5-Stars-for-Clover-Health-PPO-Medicare-Advantage-Plans-for-2025-Payment-Year.html",
        "type": "CLOV"
      },
      {
        "title": "Clover Health Investments, Corp. (CLOV) Reports Q1 Loss, Tops Revenue Estimates",
        "publisher": "Zacks Investment Research",
        "timestamp": "2024-05-07T22:05:06Z",
        "url": "https://www.zacks.com/stock/news/2270065/clover-health-investments-corp-clov-reports-q1-loss-tops-revenue-estimates",
        "type": "CLOV"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": null,
        "forwardPE": -42.62762
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  },
  {
    "symbol": "CMRX",
    "timestamp": "2025-02-04 08:50:34",
    "names": {
      "long": "Chimerix, Inc.",
      "short": "Chimerix, Inc.",
      "polygon": "Chimerix, Inc."
    },
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "description": "Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.",
    "branding": {
      "icon_url": "https://api.polygon.io/v1/reference/company-branding/Y2hpbWVyaXguY29t/images/2024-10-01_icon.jpeg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq",
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/Y2hpbWVyaXguY29t/images/2024-10-01_logo.png?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "investing_url": "https://www.investing.com/equities/chimerix-inc",
    "price": 3.83,
    "priceChange": 0.789473684210533,
    "openPrice": 3.82,
    "prevClose": 3.8,
    "dayHigh": 3.98,
    "dayLow": 3.79,
    "volume": 329272,
    "prevVolume": 1561345.0,
    "volumeMetrics": {
      "recentVolumes": [
        1033223.0,
        1335600.0,
        1197083.0,
        1561345.0,
        329272
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        29.27,
        -10.37,
        30.43,
        -78.91
      ],
      "averageVolume": 4574540.583333333,
      "volumeChange": -78.91,
      "volumeVsAvg": -92.8
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 4574540.583333333
    },
    "fiftyTwoWeekHigh": 4.22,
    "fiftyTwoWeekLow": 0.75,
    "highProximityPct": 9.241706161137433,
    "marketCap": 353595328.38,
    "insiderActivity": {
      "recent_trades": 9,
      "net_shares": 350554,
      "notable_trades": [],
      "summary": {
        "total_sales": 0,
        "total_purchases": 344389,
        "total_awards": 6165,
        "sales_count": 0,
        "purchases_count": 6,
        "awards_count": 3,
        "total_value": {
          "sales": 0.0,
          "purchases": 0.0,
          "awards": 25278.0
        }
      },
      "latest_date": "2025-01-30"
    },
    "recentNews": [
      {
        "title": "Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-10-18T20:31:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/10/18/2965738/25619/en/Chimerix-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html",
        "type": "CMRX"
      },
      {
        "title": "Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-04-24T11:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/04/24/2868440/25619/en/Chimerix-to-Report-First-Quarter-2024-Financial-Results-and-Provide-an-Operational-Update-on-May-1-2024.html",
        "type": "CMRX"
      },
      {
        "title": "Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-04-16T20:05:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/04/16/2864084/25619/en/Chimerix-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html",
        "type": "CMRX"
      },
      {
        "title": "Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-02-22T12:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/02/22/2833506/25619/en/Chimerix-to-Report-Fourth-Quarter-and-Year-End-2023-Financial-Results-and-Provide-an-Operational-Update-on-February-29-2024.html",
        "type": "CMRX"
      },
      {
        "title": "Chimerix Appoints Lisa Decker to Board of Directors",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2023-12-29T12:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2023/12/29/2802020/25619/en/Chimerix-Appoints-Lisa-Decker-to-Board-of-Directors.html",
        "type": "CMRX"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": null,
        "forwardPE": -3.4932125
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  },
  {
    "symbol": "CPRX",
    "timestamp": "2025-02-04 08:50:37",
    "names": {
      "long": "Catalyst Pharmaceuticals, Inc.",
      "short": "Catalyst Pharmaceuticals, Inc.",
      "polygon": "Catalyst Pharmaceutical  Inc."
    },
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "description": "Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing\u00a0therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.",
    "branding": {
      "icon_url": "https://api.polygon.io/v1/reference/company-branding/Y2F0YWx5c3RwaGFybWEuY29t/images/2024-10-01_icon.jpeg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq",
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/Y2F0YWx5c3RwaGFybWEuY29t/images/2024-10-01_logo.svg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "investing_url": "https://www.investing.com/equities/catalyst-pharmaceuticals",
    "price": 23,
    "priceChange": 1.679929266136158,
    "openPrice": 22.85,
    "prevClose": 22.62,
    "dayHigh": 23.19,
    "dayLow": 22.57,
    "volume": 282844,
    "prevVolume": 1187950.0,
    "volumeMetrics": {
      "recentVolumes": [
        1123369.0,
        938075,
        999390,
        1187950.0,
        282844
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        -16.49,
        6.54,
        18.87,
        -76.19
      ],
      "averageVolume": 1078733.05,
      "volumeChange": -76.19,
      "volumeVsAvg": -73.78
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 1078733.05
    },
    "fiftyTwoWeekHigh": 24.64,
    "fiftyTwoWeekLow": 13.12,
    "highProximityPct": 6.655844155844158,
    "marketCap": 2726590746.96,
    "insiderActivity": {
      "recent_trades": 40,
      "net_shares": 524433,
      "notable_trades": [
        {
          "date": "2025-01-08",
          "insider": "DENKHAUS DONALD A",
          "position": "Director",
          "type": "Stock Award",
          "shares": 50000,
          "value": 112000.0,
          "price_per_share": 2.24
        },
        {
          "date": "2024-12-13",
          "insider": "MILLER STEVEN R",
          "position": "Officer",
          "type": "Stock Award",
          "shares": 235000,
          "value": 942350.0,
          "price_per_share": 4.01
        },
        {
          "date": "2024-12-10",
          "insider": "MILLER STEVEN R",
          "position": "Officer",
          "type": "Stock Award",
          "shares": 61872,
          "value": 200500.0,
          "price_per_share": 3.2405611585208174
        },
        {
          "date": "2024-12-10",
          "insider": "O KEEFFE CHARLES B",
          "position": "Director",
          "type": "Stock Award",
          "shares": 41413,
          "value": 160400.0,
          "price_per_share": 3.873179919348997
        },
        {
          "date": "2024-12-10",
          "insider": "MILLER STEVEN R",
          "position": "Officer",
          "type": "Sale",
          "shares": 50000,
          "value": 1096350.0,
          "price_per_share": 21.927
        },
        {
          "date": "2024-11-27",
          "insider": "HARPER MOLLY",
          "position": "Director",
          "type": "Stock Award",
          "shares": 17500,
          "value": 101150.0,
          "price_per_share": 5.78
        },
        {
          "date": "2024-11-27",
          "insider": "INGENITO GARY",
          "position": "Officer",
          "type": "Sale",
          "shares": 12000,
          "value": 272654.0,
          "price_per_share": 22.721166666666665
        },
        {
          "date": "2024-11-27",
          "insider": "HARPER MOLLY",
          "position": "Director",
          "type": "Sale",
          "shares": 17500,
          "value": 385000.0,
          "price_per_share": 22.0
        },
        {
          "date": "2024-11-26",
          "insider": "ELSBERND BRIAN D",
          "position": "Officer",
          "type": "Stock Award",
          "shares": 60000,
          "value": 240600.0,
          "price_per_share": 4.01
        },
        {
          "date": "2024-11-26",
          "insider": "ELSBERND BRIAN D",
          "position": "Officer",
          "type": "Sale",
          "shares": 13256,
          "value": 286704.0,
          "price_per_share": 21.628243814121905
        },
        {
          "date": "2024-11-20",
          "insider": "MCENANY PATRICK JAMES",
          "position": "Chairman of the Board",
          "type": "Stock Award",
          "shares": 170845,
          "value": 604791.0,
          "price_per_share": 3.5399982440223594
        },
        {
          "date": "2024-11-20",
          "insider": "INGENITO GARY",
          "position": "Officer",
          "type": "Stock Award",
          "shares": 38000,
          "value": 152380.0,
          "price_per_share": 4.01
        },
        {
          "date": "2024-11-20",
          "insider": "MCENANY PATRICK JAMES",
          "position": "Chairman of the Board",
          "type": "Sale",
          "shares": 170845,
          "value": 3627259.0,
          "price_per_share": 21.231285668295822
        },
        {
          "date": "2024-11-20",
          "insider": "INGENITO GARY",
          "position": "Officer",
          "type": "Sale",
          "shares": 38000,
          "value": 805562.0,
          "price_per_share": 21.199
        },
        {
          "date": "2024-11-14",
          "insider": "MCENANY PATRICK JAMES",
          "position": "Director",
          "type": "Stock Award",
          "shares": 137155,
          "value": 485529.0,
          "price_per_share": 3.540002187306332
        },
        {
          "date": "2024-11-14",
          "insider": "MCENANY PATRICK JAMES",
          "position": "Director",
          "type": "Sale",
          "shares": 137155,
          "value": 3096801.0,
          "price_per_share": 22.578841456746016
        },
        {
          "date": "2024-11-12",
          "insider": "MCENANY PATRICK JAMES",
          "position": "Chairman of the Board",
          "type": "Stock Award",
          "shares": 492000,
          "value": 1882680.0,
          "price_per_share": 3.8265853658536586
        },
        {
          "date": "2024-11-12",
          "insider": "MCENANY PATRICK JAMES",
          "position": "Chairman of the Board",
          "type": "Sale",
          "shares": 492000,
          "value": 11510102.0,
          "price_per_share": 23.3945162601626
        }
      ],
      "summary": {
        "total_sales": 930756,
        "total_purchases": 139404,
        "total_awards": 1315785,
        "sales_count": 8,
        "purchases_count": 21,
        "awards_count": 11,
        "total_value": {
          "sales": 21080432.0,
          "purchases": 0.0,
          "awards": 4930500.0
        }
      },
      "latest_date": "2025-01-08"
    },
    "recentNews": [
      {
        "title": "Why Is Catalyst (CPRX) Up 0.7% Since Last Earnings Report?",
        "publisher": "Zacks Investment Research",
        "timestamp": "2024-06-07T15:30:52Z",
        "url": "https://www.zacks.com/stock/news/2285472/why-is-catalyst-cprx-up-07-since-last-earnings-report",
        "type": "CPRX"
      },
      {
        "title": "A Closer Look at 7 Analyst Recommendations For Catalyst Pharmaceuticals",
        "publisher": "Benzinga",
        "timestamp": "2024-06-03T13:00:46Z",
        "url": "https://www.benzinga.com/insights/analyst-ratings/24/06/39136238/a-closer-look-at-7-analyst-recommendations-for-catalyst-pharmaceuticals",
        "type": "CPRX"
      },
      {
        "title": "Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE\u00ae",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-05-30T17:41:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/05/30/2891040/13009/en/Catalyst-Pharmaceuticals-Receives-U-S-FDA-Approval-For-Increased-Maximum-Daily-Dose-For-FIRDAPSE.html",
        "type": "CPRX"
      },
      {
        "title": "Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-05-28T12:03:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/05/28/2888999/13009/en/Catalyst-Pharmaceuticals-to-Participate-at-the-Jefferies-Global-Healthcare-Conference-2024.html",
        "type": "CPRX"
      },
      {
        "title": "2 Incredible Growth Stocks to Buy Hand Over Fist Right Now",
        "publisher": "The Motley Fool",
        "timestamp": "2024-05-15T12:00:00Z",
        "url": "https://www.fool.com/investing/2024/05/15/2-incredible-growth-stocks-to-buy-hand-over-fist-r/",
        "type": "CPRX"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": 19.512712,
        "forwardPE": 11.8695965
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 2,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": true,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  },
  {
    "symbol": "CVM",
    "timestamp": "2025-02-04 08:50:39",
    "names": {
      "long": "CEL-SCI Corporation",
      "short": "Cel-Sci Corporation",
      "polygon": "Cel-Sci Corporation"
    },
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "description": "CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.",
    "branding": {
      "icon_url": "https://api.polygon.io/v1/reference/company-branding/Y2VsLXNjaS5jb20/images/2024-10-01_icon.jpeg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq",
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/Y2VsLXNjaS5jb20/images/2024-10-01_logo.png?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "investing_url": "https://www.investing.com/equities/cel-sci-corp",
    "price": 0.3801,
    "priceChange": 0.9025749933634231,
    "openPrice": 0.3851,
    "prevClose": 0.3767,
    "dayHigh": 0.3898,
    "dayLow": 0.370101,
    "volume": 87551,
    "prevVolume": 451363,
    "volumeMetrics": {
      "recentVolumes": [
        1361219.0,
        213765,
        318460,
        451363,
        87551
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        -84.3,
        48.98,
        41.73,
        -80.6
      ],
      "averageVolume": 1067375.9166666667,
      "volumeChange": -80.6,
      "volumeVsAvg": -91.8
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 1067375.9166666667
    },
    "fiftyTwoWeekHigh": 3.08,
    "fiftyTwoWeekLow": 0.36,
    "highProximityPct": 87.6590909090909,
    "marketCap": 27434426.578199998,
    "insiderActivity": {
      "recent_trades": 3,
      "net_shares": 29668,
      "notable_trades": [],
      "summary": {
        "total_sales": 0,
        "total_purchases": 0,
        "total_awards": 29668,
        "sales_count": 0,
        "purchases_count": 0,
        "awards_count": 3,
        "total_value": {
          "sales": 0.0,
          "purchases": 0.0,
          "awards": 11867.0
        }
      },
      "latest_date": "2024-12-31"
    },
    "recentNews": [
      {
        "title": "3 Interesting Emerging Growth Stock Ideas From the 2024 Think Equity Conference",
        "publisher": "Investing.com",
        "timestamp": "2024-11-04T20:52:00Z",
        "url": "https://www.investing.com/analysis/3-interesting-emerging-growth-stock-ideas-from-the-2024-think-equity-conference-200653751",
        "type": "CVM"
      },
      {
        "title": "Why U Power Shares Are Trading Lower By Around 54%? Here Are Other Stocks Moving In Monday's Mid-Day Session",
        "publisher": "Benzinga",
        "timestamp": "2023-12-04T18:10:23Z",
        "url": "https://www.benzinga.com/news/23/12/36075275/why-u-power-shares-are-trading-lower-by-around-54-here-are-other-stocks-moving-in-mondays-mid-day-se",
        "type": "OCUL"
      },
      {
        "title": "Why Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session",
        "publisher": "Benzinga",
        "timestamp": "2023-07-18T17:00:51Z",
        "url": "https://www.benzinga.com/news/23/07/33271322/why-lixte-biotechnology-shares-are-trading-lower-by-26-here-are-other-stocks-moving-in-tuesdays-mid",
        "type": "LIXT"
      },
      {
        "title": "US Stocks Mixed; Bank of America Tops Q2 Views",
        "publisher": "Benzinga",
        "timestamp": "2023-07-18T13:51:42Z",
        "url": "https://www.benzinga.com/news/earnings/23/07/33267401/us-stocks-mixed-bank-of-america-tops-q2-views",
        "type": "CVM"
      },
      {
        "title": "Why Biophytis Shares Are Trading Higher By 54%; Here Are 20 Stocks Moving Premarket",
        "publisher": "Benzinga",
        "timestamp": "2023-07-18T12:12:20Z",
        "url": "https://www.benzinga.com/news/23/07/33264705/why-biophytis-shares-are-trading-higher-by-54-here-are-20-stocks-moving-premarket",
        "type": "NMTR"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": null,
        "forwardPE": -0.8761364
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  },
  {
    "symbol": "ENOV",
    "timestamp": "2025-02-04 08:50:42",
    "names": {
      "long": "Enovis Corporation",
      "short": "Enovis Corporation",
      "polygon": "Enovis Corporation"
    },
    "sector": "Industrials",
    "industry": "Specialty Industrial Machinery",
    "description": "Enovis Corp is a medical technology company focused on developing clinically differentiated solutions that generate measurable\u00a0patient outcomes and transform workflows by manufacturing and distributing high-quality medical devices with a broad\u00a0use for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company conducts its operations through two operating segments: Prevention & Recovery (P&R) and Reconstructive (Recon). It generates the majority of revenue from the Prevention & Recovery segment.",
    "branding": {
      "icon_url": "https://api.polygon.io/v1/reference/company-branding/ZW5vdmlzLmNvbQ/images/2024-10-01_icon.jpeg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq",
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/ZW5vdmlzLmNvbQ/images/2024-10-01_logo.svg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "investing_url": "https://in.investing.com/equities/colfax",
    "price": 46.0025,
    "priceChange": 1.6180693616081168,
    "openPrice": 45.11,
    "prevClose": 45.27,
    "dayHigh": 46.0599,
    "dayLow": 45.11,
    "volume": 103093,
    "prevVolume": 487654,
    "volumeMetrics": {
      "recentVolumes": [
        554921,
        588659,
        506611,
        487654,
        103093
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        6.08,
        -13.94,
        -3.74,
        -78.86
      ],
      "averageVolume": 744048.0666666667,
      "volumeChange": -78.86,
      "volumeVsAvg": -86.14
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 744048.0666666667
    },
    "fiftyTwoWeekHigh": 65.03,
    "fiftyTwoWeekLow": 38.27,
    "highProximityPct": 29.2595725049977,
    "marketCap": 2595621247.45,
    "insiderActivity": {
      "recent_trades": 1,
      "net_shares": 513,
      "notable_trades": [],
      "summary": {
        "total_sales": 0,
        "total_purchases": 513,
        "total_awards": 0,
        "sales_count": 0,
        "purchases_count": 1,
        "awards_count": 0,
        "total_value": {
          "sales": 0.0,
          "purchases": 0.0,
          "awards": 0.0
        }
      },
      "latest_date": "2024-12-31"
    },
    "recentNews": [
      {
        "title": "Enovis\u2122 Announces Leadership Change to International Surgical Business",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2025-01-17T11:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2025/01/17/3011318/0/en/Enovis-Announces-Leadership-Change-to-International-Surgical-Business.html",
        "type": "ENOV"
      },
      {
        "title": "Manual Cutting Equipment Market to record USD 24.6 Bn by 2032, Says Global Market Insights Inc.",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-09-05T10:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/09/05/2941140/0/en/Manual-Cutting-Equipment-Market-to-record-USD-24-6-Bn-by-2032-Says-Global-Market-Insights-Inc.html",
        "type": "AIQUY"
      },
      {
        "title": "Enovis' (ENOV) New System to Aid Reverse Shoulder Prosthesis - Zacks Investment Research",
        "publisher": "Zacks Investment Research",
        "timestamp": "2024-07-15T13:30:39Z",
        "url": "https://www.zacks.com/stock/news/2301736/enovis-enov-new-system-to-aid-reverse-shoulder-prosthesis",
        "type": "ENOV"
      },
      {
        "title": "What Awaits Quest Diagnostics (DGX) in Q2 Earnings Release? - Zacks Investment Research",
        "publisher": "Zacks Investment Research",
        "timestamp": "2024-07-12T13:02:00Z",
        "url": "https://www.zacks.com/stock/news/2300741/what-awaits-quest-diagnostics-dgx-in-q2-earnings-release",
        "type": "DGX"
      },
      {
        "title": "5 Medical Info Systems Stock to Buy for a Stable Portfolio",
        "publisher": "Zacks Investment Research",
        "timestamp": "2024-06-24T12:16:00Z",
        "url": "https://www.zacks.com/stock/news/2292098/5-medical-info-systems-stock-to-buy-for-a-stable-portfolio",
        "type": "PHR"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": null,
        "forwardPE": 14.544453
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  },
  {
    "symbol": "ETNB",
    "timestamp": "2025-02-04 08:50:45",
    "names": {
      "long": "89bio, Inc.",
      "short": "89bio, Inc.",
      "polygon": "89bio, Inc. Common Stock"
    },
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "description": "89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of\u00a0therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).",
    "branding": {
      "icon_url": "https://api.polygon.io/v1/reference/company-branding/ODliaW8uY29t/images/2024-10-01_icon.jpeg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq",
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/ODliaW8uY29t/images/2024-10-01_logo.svg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "investing_url": "https://www.investing.com/equities/89bio-inc",
    "price": 9.905,
    "priceChange": 6.6200215285252995,
    "openPrice": 9.61,
    "prevClose": 9.29,
    "dayHigh": 9.955,
    "dayLow": 9.38,
    "volume": 2209329.0,
    "prevVolume": 2496874.0,
    "volumeMetrics": {
      "recentVolumes": [
        7489360.0,
        6262583.0,
        2825914.0,
        2496874.0,
        2209329.0
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        -16.38,
        -54.88,
        -11.64,
        -11.52
      ],
      "averageVolume": 1884416.2,
      "volumeChange": -11.52,
      "volumeVsAvg": 17.24
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 1884416.2
    },
    "fiftyTwoWeekHigh": 16.63,
    "fiftyTwoWeekLow": 5.986,
    "highProximityPct": 40.438965724594105,
    "marketCap": 1343797703.2,
    "insiderActivity": {
      "recent_trades": 9,
      "net_shares": 6050248,
      "notable_trades": [
        {
          "date": "2025-01-30",
          "insider": "RA CAPITAL MANAGEMENT, L.P.",
          "position": "Beneficial Owner of more than 10% of a Class of Security",
          "type": "Stock Award",
          "shares": 5714285,
          "value": 49999994.0,
          "price_per_share": 8.750000043750006
        }
      ],
      "summary": {
        "total_sales": 0,
        "total_purchases": 285000,
        "total_awards": 5765248,
        "sales_count": 0,
        "purchases_count": 3,
        "awards_count": 6,
        "total_value": {
          "sales": 0.0,
          "purchases": 0.0,
          "awards": 50373944.0
        }
      },
      "latest_date": "2025-01-30"
    },
    "recentNews": [
      {
        "title": "Rare Endocrinology and Metabolic Disorders Market Analysis: Emerging Trends and Future Outlook of Hypophosphatasia, Congenital Adrenal Hyperplasia, and Severe Hypertriglyceridemia | DelveInsight",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2025-01-09T18:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2025/01/09/3007282/0/en/Rare-Endocrinology-and-Metabolic-Disorders-Market-Analysis-Emerging-Trends-and-Future-Outlook-of-Hypophosphatasia-Congenital-Adrenal-Hyperplasia-and-Severe-Hypertriglyceridemia-Del.html",
        "type": "AZN"
      },
      {
        "title": "89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-11-29T18:30:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/11/29/2989260/0/en/89bio-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html",
        "type": "ETNB"
      },
      {
        "title": "89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-11-13T04:58:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/11/13/2979902/0/en/89bio-Inc-Announces-Upsized-Pricing-of-125-0-Million-Public-Offering-of-Common-Stock-and-Pre-Funded-Warrants.html",
        "type": "ETNB"
      },
      {
        "title": "89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-06-14T20:05:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/06/14/2899184/0/en/89bio-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html",
        "type": "ETNB"
      },
      {
        "title": "89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-05-22T20:05:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/05/22/2886846/0/en/89bio-to-Present-48-Week-Data-from-ENLIVEN-Phase-2b-Pegozafermin-Trial-in-Metabolic-Dysfunction-Associated-Steatohepatitis-MASH-at-EASL-International-Liver-Congress.html",
        "type": "ETNB"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": null,
        "forwardPE": -3.8228474
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": true,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  },
  {
    "symbol": "EVH",
    "timestamp": "2025-02-04 08:50:47",
    "names": {
      "long": "Evolent Health, Inc.",
      "short": "Evolent Health, Inc",
      "polygon": "Evolent Health, Inc Class A Common Stock"
    },
    "sector": "Healthcare",
    "industry": "Health Information Services",
    "description": "Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.",
    "branding": {
      "icon_url": "https://api.polygon.io/v1/reference/company-branding/ZXZvbGVudGhlYWx0aC5jb20/images/2024-10-01_icon.jpeg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq",
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/ZXZvbGVudGhlYWx0aC5jb20/images/2024-10-01_logo.png?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "investing_url": "https://www.investing.com/equities/evolent-health-inc",
    "price": 10.32,
    "priceChange": 1.0773751224289856,
    "openPrice": 10.08,
    "prevClose": 10.21,
    "dayHigh": 10.4412,
    "dayLow": 10.08,
    "volume": 127482,
    "prevVolume": 1418832.0,
    "volumeMetrics": {
      "recentVolumes": [
        1697175.0,
        1098905.0,
        1692118.0,
        1418832.0,
        127482
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        -35.25,
        53.98,
        -16.15,
        -91.02
      ],
      "averageVolume": 2774993.8666666667,
      "volumeChange": -91.02,
      "volumeVsAvg": -95.41
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 2774993.8666666667
    },
    "fiftyTwoWeekHigh": 35.0,
    "fiftyTwoWeekLow": 9.74,
    "highProximityPct": 70.51428571428572,
    "marketCap": 1192823021.36,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": [],
      "summary": {
        "total_sales": 0,
        "total_purchases": 0,
        "total_awards": 0,
        "sales_count": 0,
        "purchases_count": 0,
        "awards_count": 0
      }
    },
    "recentNews": [
      {
        "title": "Dr. Abeer AbouYabis Scholarship for Future Doctors Inspires Aspiring Physicians to Tackle Healthcare Challenges",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2025-01-13T03:19:00Z",
        "url": "https://www.globenewswire.com/news-release/2025/01/13/3008090/0/en/Dr-Abeer-AbouYabis-Scholarship-for-Future-Doctors-Inspires-Aspiring-Physicians-to-Tackle-Healthcare-Challenges.html",
        "type": "EVH"
      },
      {
        "title": "Global Technology Spending On Core Administration in Healthcare Market Size To Worth USD 61.5 Billion By 2033 | CAGR Of 5.86%",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-08-12T22:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/08/12/2928829/0/en/Global-Technology-Spending-On-Core-Administration-in-Healthcare-Market-Size-To-Worth-USD-61-5-Billion-By-2033-CAGR-Of-5-86.html",
        "type": "EVH"
      },
      {
        "title": "Evolent Health (EVH) Reports Q1 Earnings: What Key Metrics Have to Say",
        "publisher": "Zacks Investment Research",
        "timestamp": "2024-05-10T13:30:09Z",
        "url": "https://www.zacks.com/stock/news/2272113/evolent-health-evh-reports-q1-earnings-what-key-metrics-have-to-say",
        "type": "EVH"
      },
      {
        "title": "Evolent Health (EVH) Q1 2024 Earnings Call Transcript",
        "publisher": "The Motley Fool",
        "timestamp": "2024-05-10T02:30:13Z",
        "url": "https://www.fool.com/earnings/call-transcripts/2024/05/09/evolent-health-evh-q1-2024-earnings-call-transcrip/",
        "type": "EVH"
      },
      {
        "title": "Evolent Health (EVH) Q1 Earnings and Revenues Top Estimates",
        "publisher": "Zacks Investment Research",
        "timestamp": "2024-05-09T22:50:05Z",
        "url": "https://www.zacks.com/stock/news/2271857/evolent-health-evh-q1-earnings-and-revenues-top-estimates",
        "type": "EVH"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": null,
        "forwardPE": 16.174603
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  },
  {
    "symbol": "EXEL",
    "timestamp": "2025-02-04 08:50:50",
    "names": {
      "long": "Exelixis, Inc.",
      "short": "Exelixis, Inc.",
      "polygon": "Exelixis Inc"
    },
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "description": "Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.",
    "branding": {
      "icon_url": "https://api.polygon.io/v1/reference/company-branding/ZXhlbGl4aXMuY29t/images/2024-10-01_icon.jpeg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq",
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/ZXhlbGl4aXMuY29t/images/2024-10-01_logo.svg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "investing_url": "https://www.investing.com/equities/exelixis-inc",
    "price": 33.21,
    "priceChange": 1.0036496350364912,
    "openPrice": 33.35,
    "prevClose": 32.88,
    "dayHigh": 33.6,
    "dayLow": 32.95,
    "volume": 411835,
    "prevVolume": 1925461.0,
    "volumeMetrics": {
      "recentVolumes": [
        2193235.0,
        2075676.0,
        2304353.0,
        1925461.0,
        411835
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        -5.36,
        11.02,
        -16.44,
        -78.61
      ],
      "averageVolume": 2126819.35,
      "volumeChange": -78.61,
      "volumeVsAvg": -80.64
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 2126819.35
    },
    "fiftyTwoWeekHigh": 37.59,
    "fiftyTwoWeekLow": 20.02,
    "highProximityPct": 11.652035115722272,
    "marketCap": 9435530820.8,
    "insiderActivity": {
      "recent_trades": 11,
      "net_shares": 1165349,
      "notable_trades": [
        {
          "date": "2024-11-29",
          "insider": "HESSEKIEL JEFFREY J",
          "position": "General Counsel",
          "type": "Sale",
          "shares": 60000,
          "value": 2200200.0,
          "price_per_share": 36.67
        },
        {
          "date": "2024-11-27",
          "insider": "HESSEKIEL JEFFREY J",
          "position": "General Counsel",
          "type": "Stock Award",
          "shares": 129314,
          "value": 2431103.0,
          "price_per_share": 18.79999845337705
        },
        {
          "date": "2024-11-22",
          "insider": "HALEY PATRICK JOSEPH",
          "position": "Officer",
          "type": "Sale",
          "shares": 10000,
          "value": 352700.0,
          "price_per_share": 35.27
        },
        {
          "date": "2024-11-18",
          "insider": "HALEY PATRICK JOSEPH",
          "position": "Officer",
          "type": "Sale",
          "shares": 41588,
          "value": 1428822.0,
          "price_per_share": 34.35659324805232
        }
      ],
      "summary": {
        "total_sales": 111588,
        "total_purchases": 1147623,
        "total_awards": 129314,
        "sales_count": 3,
        "purchases_count": 7,
        "awards_count": 1,
        "total_value": {
          "sales": 3981722.0,
          "purchases": 0.0,
          "awards": 2431103.0
        }
      },
      "latest_date": "2025-01-16"
    },
    "recentNews": [
      {
        "title": "2 Biotech Stocks to Buy Hand Over Fist in December",
        "publisher": "The Motley Fool",
        "timestamp": "2024-12-07T13:45:00Z",
        "url": "https://www.fool.com/investing/2024/12/07/2-biotech-stocks-to-buy-hand-over-fist-in-december/?source=iedfolrf0000001",
        "type": "CRSP"
      },
      {
        "title": "Neuroendocrine Tumors Market to Showcase Rapid Growth During the Study Period (2020\u20132034), at a CAGR of 5.1%| DelveInsight",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-11-25T18:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/11/25/2986962/0/en/Neuroendocrine-Tumors-Market-to-Showcase-Rapid-Growth-During-the-Study-Period-2020-2034-at-a-CAGR-of-5-1-DelveInsight.html",
        "type": "NVS"
      },
      {
        "title": "3 Magnificent Stocks Under $100 to Buy in November",
        "publisher": "The Motley Fool",
        "timestamp": "2024-11-03T11:41:00Z",
        "url": "https://www.fool.com/investing/2024/11/03/3-magnificent-stocks-under-100-to-buy-in-november/?source=iedfolrf0000001",
        "type": "AZN"
      },
      {
        "title": "Reddit, Roblox And Garmin Are Among Top 10 Large Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio?",
        "publisher": "Benzinga",
        "timestamp": "2024-11-03T08:30:17Z",
        "url": "https://www.benzinga.com/news/large-cap/24/11/41702042/reddit-roblox-and-garmin-are-among-top-10-large-cap-gainers-last-week-oct-28-nov-1-are-the-others-",
        "type": "RDDT"
      },
      {
        "title": "1 No-Brainer Stock to Buy With $40",
        "publisher": "The Motley Fool",
        "timestamp": "2024-10-23T13:53:00Z",
        "url": "https://www.fool.com/investing/2024/10/23/1-no-brainer-stock-to-buy-with-40/?source=iedfolrf0000001",
        "type": "EXEL"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": 21.370968,
        "forwardPE": 15.071067
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 2,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": true,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  },
  {
    "symbol": "EYPT",
    "timestamp": "2025-02-04 08:50:53",
    "names": {
      "long": "EyePoint Pharmaceuticals, Inc.",
      "short": "EyePoint Pharmaceuticals, Inc.",
      "polygon": "EyePoint Pharmaceuticals, Inc. Common Stock"
    },
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "description": "EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.",
    "branding": {
      "icon_url": "https://api.polygon.io/v1/reference/company-branding/ZXllcG9pbnRwaGFybWEuY29t/images/2024-10-01_icon.jpeg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq",
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/ZXllcG9pbnRwaGFybWEuY29t/images/2024-10-01_logo.png?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "investing_url": "https://uk.investing.com/equities/psivida-corp",
    "price": 7.42,
    "priceChange": 3.486750348675035,
    "openPrice": 7.19,
    "prevClose": 7.17,
    "dayHigh": 7.425,
    "dayLow": 7.11,
    "volume": 104649,
    "prevVolume": 761987,
    "volumeMetrics": {
      "recentVolumes": [
        320064,
        516400,
        614526,
        761987,
        104649
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        61.34,
        19.0,
        24.0,
        -86.27
      ],
      "averageVolume": 790632.15,
      "volumeChange": -86.27,
      "volumeVsAvg": -86.76
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 790632.15
    },
    "fiftyTwoWeekHigh": 30.99,
    "fiftyTwoWeekLow": 6.9,
    "highProximityPct": 76.05679251371411,
    "marketCap": 498232526.3,
    "insiderActivity": {
      "recent_trades": 4,
      "net_shares": 178880,
      "notable_trades": [],
      "summary": {
        "total_sales": 0,
        "total_purchases": 178880,
        "total_awards": 0,
        "sales_count": 0,
        "purchases_count": 4,
        "awards_count": 0,
        "total_value": {
          "sales": 0.0,
          "purchases": 0.0,
          "awards": 0.0
        }
      },
      "latest_date": "2025-01-06"
    },
    "recentNews": [
      {
        "title": "EyePoint to Present at Guggenheim SMID Cap Biotech Conference",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2025-01-30T12:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2025/01/30/3017863/0/en/EyePoint-to-Present-at-Guggenheim-SMID-Cap-Biotech-Conference.html",
        "type": "EYPT"
      },
      {
        "title": "EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2025-01-16T12:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2025/01/16/3010670/0/en/EyePoint-Pharmaceuticals-Reports-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635-c-4.html",
        "type": "EYPT"
      },
      {
        "title": "EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-10-30T01:47:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/10/30/2971359/0/en/EyePoint-Pharmaceuticals-Announces-Pricing-of-Upsized-Public-Offering.html",
        "type": "EYPT"
      },
      {
        "title": "EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock",
        "publisher": "Benzinga",
        "timestamp": "2024-10-28T21:14:19Z",
        "url": "https://www.benzinga.com/pressreleases/24/10/g41588396/eyepoint-pharmaceuticals-announces-proposed-public-offering-of-common-stock",
        "type": "EYPT"
      },
      {
        "title": "EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-08-27T11:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/08/27/2936080/0/en/EyePoint-Pharmaceuticals-Announces-Participation-at-Upcoming-Investor-Conferences.html",
        "type": "EYPT"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": null,
        "forwardPE": -3.0647418
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  },
  {
    "symbol": "GALT",
    "timestamp": "2025-02-04 08:50:55",
    "names": {
      "long": "Galectin Therapeutics Inc.",
      "short": "Galectin Therapeutics Inc.",
      "polygon": "Galectin Therapeutics Inc."
    },
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "description": null,
    "branding": {
      "icon_url": null,
      "logo_url": null
    },
    "investing_url": "https://www.investing.com/equities/galectin-therapeutics-inc.",
    "price": 1.225,
    "priceChange": -0.4065040650406418,
    "openPrice": 1.26,
    "prevClose": 1.23,
    "dayHigh": 1.26,
    "dayLow": 1.22,
    "volume": 31857,
    "prevVolume": 260231,
    "volumeMetrics": {
      "recentVolumes": [
        144496,
        229518,
        228585,
        260231,
        31857
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        58.84,
        -0.41,
        13.84,
        -87.76
      ],
      "averageVolume": 742267.1166666667,
      "volumeChange": -87.76,
      "volumeVsAvg": -95.71
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 742267.1166666667
    },
    "fiftyTwoWeekHigh": 4.27,
    "fiftyTwoWeekLow": 0.73,
    "highProximityPct": 71.31147540983605,
    "marketCap": 0,
    "insiderActivity": {
      "recent_trades": 11,
      "net_shares": 318143,
      "notable_trades": [],
      "summary": {
        "total_sales": 0,
        "total_purchases": 136000,
        "total_awards": 182143,
        "sales_count": 0,
        "purchases_count": 3,
        "awards_count": 8,
        "total_value": {
          "sales": 0.0,
          "purchases": 0.0,
          "awards": 172029.0
        }
      },
      "latest_date": "2025-01-23"
    },
    "recentNews": [
      {
        "title": "Galectin Therapeutics to Present at the 2025 MASH-TAG Conference",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2025-01-10T13:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2025/01/10/3007611/27423/en/Galectin-Therapeutics-to-Present-at-the-2025-MASH-TAG-Conference.html",
        "type": "GALT"
      },
      {
        "title": "Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-08-13T12:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/08/13/2929111/27423/en/Galectin-Therapeutics-Reports-Financial-Results-for-the-Quarter-Ended-June-30-2024-and-Provides-Business-Update.html",
        "type": "GALT"
      },
      {
        "title": "Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-06-04T12:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/06/04/2892953/27423/en/Galectin-Therapeutics-to-Present-at-the-European-Association-for-the-Study-of-the-Liver-EASL-2024-Congress.html",
        "type": "GALT"
      },
      {
        "title": "Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-05-15T12:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/05/15/2882344/27423/en/Galectin-Therapeutics-Reports-Financial-Results-for-the-Quarter-Ended-March-31-2024-and-Provides-Business-Update.html",
        "type": "GALT"
      },
      {
        "title": "Wall Street Breakfast: The Week Ahead",
        "publisher": "Seeking Alpha",
        "timestamp": "2024-04-14T11:51:01Z",
        "url": "https://seekingalpha.com/article/4683674-wall-street-breakfast-week-ahead",
        "type": "NFLX"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": null,
        "forwardPE": -0.7291667
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  },
  {
    "symbol": "GERN",
    "timestamp": "2025-02-04 08:50:58",
    "names": {
      "long": "Geron Corporation",
      "short": "Geron Corporation",
      "polygon": "Geron Corp"
    },
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "description": "Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's\u00a0drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various\u00a0rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.",
    "branding": {
      "icon_url": "https://api.polygon.io/v1/reference/company-branding/Z2Vyb24uY29t/images/2024-10-01_icon.jpeg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq",
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/Z2Vyb24uY29t/images/2024-10-01_logo.png?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "investing_url": "https://www.investing.com/equities/geron-corp",
    "price": 2.905,
    "priceChange": 1.9298245614034988,
    "openPrice": 2.85,
    "prevClose": 2.85,
    "dayHigh": 2.94,
    "dayLow": 2.82,
    "volume": 2808296.0,
    "prevVolume": 19252152.0,
    "volumeMetrics": {
      "recentVolumes": [
        10404249.0,
        10042032.0,
        10598309.0,
        19252152.0,
        2808296.0
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        -3.48,
        5.54,
        81.65,
        -85.41
      ],
      "averageVolume": 10432221.766666668,
      "volumeChange": -85.41,
      "volumeVsAvg": -73.08
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 10432221.766666668
    },
    "fiftyTwoWeekHigh": 5.34,
    "fiftyTwoWeekLow": 1.64,
    "highProximityPct": 45.59925093632959,
    "marketCap": 1762120461.64,
    "insiderActivity": {
      "recent_trades": 1,
      "net_shares": 2206,
      "notable_trades": [],
      "summary": {
        "total_sales": 0,
        "total_purchases": 2206,
        "total_awards": 0,
        "sales_count": 0,
        "purchases_count": 1,
        "awards_count": 0,
        "total_value": {
          "sales": 0.0,
          "purchases": 0.0,
          "awards": 0.0
        }
      },
      "latest_date": "2024-12-31"
    },
    "recentNews": [
      {
        "title": "Tesla Posts Weak Earnings, Joins Visa, Deutsche Bank And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga",
        "publisher": "Benzinga",
        "timestamp": "2024-07-24T12:17:24Z",
        "url": "https://www.benzinga.com/news/24/07/39930082/tesla-posts-weak-earnings-joins-visa-deutsche-bank-and-other-big-stocks-moving-lower-in-wednesdays-p",
        "type": "TSLA"
      },
      {
        "title": "Geron (GERN) Wins FDA Approval for Blood Cancer Drug, Stock Up",
        "publisher": "Zacks Investment Research",
        "timestamp": "2024-06-10T15:58:00Z",
        "url": "https://www.zacks.com/stock/news/2286219/geron-gern-wins-fda-approval-for-blood-cancer-drug-stock-up",
        "type": "BMY"
      },
      {
        "title": "Critical Insights From Geron Analyst Ratings: What You Need To Know",
        "publisher": "Benzinga",
        "timestamp": "2024-06-10T13:00:13Z",
        "url": "https://www.benzinga.com/insights/analyst-ratings/24/06/39249851/critical-insights-from-geron-analyst-ratings-what-you-need-to-know",
        "type": "GERN"
      },
      {
        "title": "Is Geron Stock a Buy Following Its First New Drug Approval?",
        "publisher": "The Motley Fool",
        "timestamp": "2024-06-08T10:37:00Z",
        "url": "https://www.fool.com/investing/2024/06/08/gerons-first-drug-is-approved-but-is-the-stock-a-b/",
        "type": "GERN"
      },
      {
        "title": "Why Is Exact Sciences (EXAS) Down 17.5% Since Last Earnings Report?",
        "publisher": "Zacks Investment Research",
        "timestamp": "2024-06-07T15:30:54Z",
        "url": "https://www.zacks.com/stock/news/2285465/why-is-exact-sciences-exas-down-175-since-last-earnings-report",
        "type": "EXAS"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": null,
        "forwardPE": -38.888145
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  },
  {
    "symbol": "GH",
    "timestamp": "2025-02-04 08:51:01",
    "names": {
      "long": "Guardant Health, Inc.",
      "short": "Guardant Health, Inc.",
      "polygon": "Guardant Health, Inc. Common Stock"
    },
    "sector": "Healthcare",
    "industry": "Diagnostics & Research",
    "description": "Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.",
    "branding": {
      "icon_url": "https://api.polygon.io/v1/reference/company-branding/Z3VhcmRhbnRoZWFsdGguY29t/images/2024-10-01_icon.jpeg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq",
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/Z3VhcmRhbnRoZWFsdGguY29t/images/2024-10-01_logo.png?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "investing_url": "https://www.investing.com/equities/gh-research",
    "price": 47.125,
    "priceChange": -0.9354635274332569,
    "openPrice": 48.45,
    "prevClose": 47.57,
    "dayHigh": 48.45,
    "dayLow": 46.8512,
    "volume": 415370,
    "prevVolume": 1813435.0,
    "volumeMetrics": {
      "recentVolumes": [
        1468873.0,
        3237144.0,
        2363960.0,
        1813435.0,
        415370
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        120.38,
        -26.97,
        -23.29,
        -77.09
      ],
      "averageVolume": 2073442.1833333333,
      "volumeChange": -77.09,
      "volumeVsAvg": -79.97
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 2073442.1833333333
    },
    "fiftyTwoWeekHigh": 50.89,
    "fiftyTwoWeekLow": 15.81,
    "highProximityPct": 7.398310080565927,
    "marketCap": 5899732723.0,
    "insiderActivity": {
      "recent_trades": 36,
      "net_shares": 240747,
      "notable_trades": [
        {
          "date": "2024-11-18",
          "insider": "KALIA KUMUD",
          "position": "Chief Technology Officer",
          "type": "Sale",
          "shares": 7000,
          "value": 204722.0,
          "price_per_share": 29.246
        },
        {
          "date": "2024-11-12",
          "insider": "CLARK IAN THORNTON",
          "position": "Director",
          "type": "Sale",
          "shares": 8318,
          "value": 244930.0,
          "price_per_share": 29.445780235633567
        }
      ],
      "summary": {
        "total_sales": 20866,
        "total_purchases": 260537,
        "total_awards": 1076,
        "sales_count": 7,
        "purchases_count": 28,
        "awards_count": 1,
        "total_value": {
          "sales": 629439.0,
          "purchases": 0.0,
          "awards": 4498.0
        }
      },
      "latest_date": "2025-01-17"
    },
    "recentNews": [
      {
        "title": "Okla And Rigetti Computing Are Among Top 8 Mid Cap Gainers Last Week (Jan 20-Jan 24): Are The Others In Your Portfolio?",
        "publisher": "Benzinga",
        "timestamp": "2025-01-26T14:45:17Z",
        "url": "https://www.benzinga.com/news/mid-cap/25/01/43218617/okla-and-rigetti-computing-are-among-top-8-mid-cap-gainers-last-week-jan-20-jan-24-are-the-others-in",
        "type": "OKLO"
      },
      {
        "title": "Cancer Biopsy Market Size is Expected to Reach USD 60.92 Billion by 2033, Growing at a CAGR of 7.81%: Straits Research",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2025-01-20T15:35:00Z",
        "url": "https://www.globenewswire.com/news-release/2025/01/20/3012174/0/en/Cancer-Biopsy-Market-Size-is-Expected-to-Reach-USD-60-92-Billion-by-2033-Growing-at-a-CAGR-of-7-81-Straits-Research.html",
        "type": "QGEN"
      },
      {
        "title": "Personalized Medicines Market to Surpass Valuation of USD 1352.81 Billion by 2031 | SkyQuest Technology",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-11-27T00:30:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/11/27/2987913/0/en/Personalized-Medicines-Market-to-Surpass-Valuation-of-USD-1352-81-Billion-by-2031-SkyQuest-Technology.html",
        "type": "BMY"
      },
      {
        "title": "Gene Panel Market to Surpass USD 11.75 Billion by 2031 | SkyQuest Technology",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-11-22T07:27:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/11/22/2985740/0/en/Gene-Panel-Market-to-Surpass-USD-11-75-Billion-by-2031-SkyQuest-Technology.html",
        "type": "QGEN"
      },
      {
        "title": "Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought",
        "publisher": "The Motley Fool",
        "timestamp": "2024-11-12T16:55:00Z",
        "url": "https://www.fool.com/investing/2024/11/12/cathie-wood-goes-bargain-hunting-3-stocks-she-just/?source=iedfolrf0000001",
        "type": "TTD"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": null,
        "forwardPE": -23.49746
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 2,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": true,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  },
  {
    "symbol": "GILD",
    "timestamp": "2025-02-04 08:51:03",
    "names": {
      "long": "Gilead Sciences, Inc.",
      "short": "Gilead Sciences, Inc.",
      "polygon": "Gilead Sciences Inc"
    },
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "description": "Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).",
    "branding": {
      "icon_url": "https://api.polygon.io/v1/reference/company-branding/Z2lsZWFkLmNvbQ/images/2024-10-01_icon.png?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq",
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/Z2lsZWFkLmNvbQ/images/2024-10-01_logo.svg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "investing_url": "https://www.investing.com/equities/gilead-sciences-inc",
    "price": 97.77,
    "priceChange": -0.620044724537507,
    "openPrice": 98.38,
    "prevClose": 98.38,
    "dayHigh": 98.47,
    "dayLow": 97.05,
    "volume": 1872982.0,
    "prevVolume": 10193880.0,
    "volumeMetrics": {
      "recentVolumes": [
        5528172.0,
        4704856.0,
        9308114.0,
        10193880.0,
        1872982.0
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        -14.89,
        97.84,
        9.52,
        -81.63
      ],
      "averageVolume": 6452808.116666666,
      "volumeChange": -81.63,
      "volumeVsAvg": -70.97
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 6452808.116666666
    },
    "fiftyTwoWeekHigh": 99.45,
    "fiftyTwoWeekLow": 62.07,
    "highProximityPct": 1.6892911010558138,
    "marketCap": 122182760000.0,
    "insiderActivity": {
      "recent_trades": 18,
      "net_shares": -1095045,
      "notable_trades": [
        {
          "date": "2025-01-31",
          "insider": "DICKINSON ANDREW D",
          "position": "Chief Financial Officer",
          "type": "Sale",
          "shares": 142180,
          "value": 13822740.0,
          "price_per_share": 97.22000281333521
        },
        {
          "date": "2025-01-31",
          "insider": "DICKINSON ANDREW D",
          "position": "Chief Financial Officer",
          "type": "Sale",
          "shares": 142180,
          "value": 9600576.0,
          "price_per_share": 67.52409621606414
        },
        {
          "date": "2025-01-15",
          "insider": "DICKINSON ANDREW D",
          "position": "Chief Financial Officer",
          "type": "Sale",
          "shares": 2500,
          "value": 228375.0,
          "price_per_share": 91.35
        },
        {
          "date": "2024-12-16",
          "insider": "DICKINSON ANDREW D",
          "position": "Chief Financial Officer",
          "type": "Sale",
          "shares": 8500,
          "value": 781660.0,
          "price_per_share": 91.96
        },
        {
          "date": "2024-11-29",
          "insider": "DICKINSON ANDREW D",
          "position": "Chief Financial Officer",
          "type": "Sale",
          "shares": 248645,
          "value": 23065271.0,
          "price_per_share": 92.76386414365864
        },
        {
          "date": "2024-11-29",
          "insider": "DICKINSON ANDREW D",
          "position": "Chief Financial Officer",
          "type": "Sale",
          "shares": 248645,
          "value": 17528577.0,
          "price_per_share": 70.4963984797603
        },
        {
          "date": "2024-11-27",
          "insider": "PARSEY MERDAD V",
          "position": "Officer",
          "type": "Sale",
          "shares": 164211,
          "value": 15094013.0,
          "price_per_share": 91.91840376101479
        },
        {
          "date": "2024-11-27",
          "insider": "PARSEY MERDAD V",
          "position": "Officer",
          "type": "Sale",
          "shares": 145413,
          "value": 9079689.0,
          "price_per_share": 62.440696498937506
        },
        {
          "date": "2024-11-26",
          "insider": "BLUESTONE JEFFREY",
          "position": "Director",
          "type": "Sale",
          "shares": 6788,
          "value": 620356.0,
          "price_per_share": 91.39010017678255
        },
        {
          "date": "2024-11-26",
          "insider": "BLUESTONE JEFFREY",
          "position": "Director",
          "type": "Sale",
          "shares": 10000,
          "value": 612442.0,
          "price_per_share": 61.2442
        }
      ],
      "summary": {
        "total_sales": 1119062,
        "total_purchases": 24017,
        "total_awards": 0,
        "sales_count": 10,
        "purchases_count": 8,
        "awards_count": 0,
        "total_value": {
          "sales": 90433699.0,
          "purchases": 0.0,
          "awards": 0.0
        }
      },
      "latest_date": "2025-01-31"
    },
    "recentNews": [
      {
        "title": "Global Pharma & Biotech CRM Software Market To Surpass Valuation of US$ 20.0 Billion by 2033 | Astute Analytica",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2025-01-17T08:30:00Z",
        "url": "https://www.globenewswire.com/news-release/2025/01/17/3011258/0/en/Global-Pharma-Biotech-CRM-Software-Market-To-Surpass-Valuation-of-US-20-0-Billion-by-2033-Astute-Analytica.html",
        "type": "JNJ"
      },
      {
        "title": "Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference",
        "publisher": "Benzinga",
        "timestamp": "2025-01-09T19:12:20Z",
        "url": "https://www.benzinga.com/general/biotech/25/01/42901177/obesity-treatments-ma-activity-to-take-center-stage-during-upcoming-jpm-healthcare-conference",
        "type": "AMGN"
      },
      {
        "title": "NUT Midline Carcinoma Treatment Market Research Report 2023-2024 & 2034: Market Forecast by Treatment, Route of Administration, and End-User Across 5 Regions and 17+ Countries",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2025-01-09T15:53:00Z",
        "url": "https://www.globenewswire.com/news-release/2025/01/09/3007196/28124/en/NUT-Midline-Carcinoma-Treatment-Market-Research-Report-2023-2024-2034-Market-Forecast-by-Treatment-Route-of-Administration-and-End-User-Across-5-Regions-and-17-Countries.html",
        "type": "NVS"
      },
      {
        "title": "Galapagos Unveils 2025 Split To Accelerate Innovation, Sharpen Strategic Focus",
        "publisher": "Benzinga",
        "timestamp": "2025-01-08T19:07:38Z",
        "url": "https://www.benzinga.com/25/01/42883679/galapagos-unveils-2025-split-to-accelerate-innovation-sharpen-strategic-focus",
        "type": "GLPG"
      },
      {
        "title": "Galapagos wil aandeelhouderswaarde ontgrendelen met voornemen tot splitsing in twee beursgenoteerde entiteiten",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2025-01-08T06:30:00Z",
        "url": "https://www.globenewswire.com/news-release/2025/01/08/3005962/0/nl/Galapagos-wil-aandeelhouderswaarde-ontgrendelen-met-voornemen-tot-splitsing-in-twee-beursgenoteerde-entiteiten.html",
        "type": "GLPG"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": 1084.5555,
        "forwardPE": 12.822517
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 3,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": true,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": true
    }
  },
  {
    "symbol": "GLUE",
    "timestamp": "2025-02-04 08:51:06",
    "names": {
      "long": "Monte Rosa Therapeutics, Inc.",
      "short": "Monte Rosa Therapeutics, Inc.",
      "polygon": "Monte Rosa Therapeutics, Inc. Common Stock"
    },
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "description": "Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.",
    "branding": {
      "icon_url": "https://api.polygon.io/v1/reference/company-branding/bW9udGVyb3NhdHguY29t/images/2024-10-01_icon.jpeg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq",
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/bW9udGVyb3NhdHguY29t/images/2024-10-01_logo.png?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "investing_url": "https://www.investing.com/equities/monte-rosa-therapeutics",
    "price": 6.67,
    "priceChange": 2.4577572964669763,
    "openPrice": 6.57,
    "prevClose": 6.51,
    "dayHigh": 6.75,
    "dayLow": 6.485,
    "volume": 84097,
    "prevVolume": 391658,
    "volumeMetrics": {
      "recentVolumes": [
        607128,
        629122,
        915493,
        391658,
        84097
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        3.62,
        45.52,
        -57.22,
        -78.53
      ],
      "averageVolume": 1064379.4166666667,
      "volumeChange": -78.53,
      "volumeVsAvg": -92.1
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 1064379.4166666667
    },
    "fiftyTwoWeekHigh": 12.4,
    "fiftyTwoWeekLow": 3.21,
    "highProximityPct": 46.20967741935484,
    "marketCap": 413162076.5,
    "insiderActivity": {
      "recent_trades": 6,
      "net_shares": 277850,
      "notable_trades": [],
      "summary": {
        "total_sales": 0,
        "total_purchases": 277850,
        "total_awards": 0,
        "sales_count": 0,
        "purchases_count": 6,
        "awards_count": 0,
        "total_value": {
          "sales": 0.0,
          "purchases": 0.0,
          "awards": 0.0
        }
      },
      "latest_date": "2025-01-02"
    },
    "recentNews": [
      {
        "title": "Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2025-01-06T12:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2025/01/06/3004444/0/en/Monte-Rosa-Therapeutics-to-Present-at-the-43rd-Annual-J-P-Morgan-Healthcare-Conference.html",
        "type": "GLUE"
      },
      {
        "title": "Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-12-11T12:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/12/11/2995243/0/en/Monte-Rosa-Therapeutics-Presents-Preclinical-Data-at-the-2024-San-Antonio-Breast-Cancer-Symposium-on-the-Potential-of-its-CDK2-directed-Molecular-Glue-Degraders-to-Treat-HR-positiv.html",
        "type": "GLUE"
      },
      {
        "title": "Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-11-26T12:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/11/26/2987333/0/en/Monte-Rosa-Therapeutics-to-Participate-in-the-Piper-Sandler-Healthcare-Conference.html",
        "type": "GLUE"
      },
      {
        "title": "Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-08-19T11:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/08/19/2932006/0/en/Monte-Rosa-Therapeutics-Announces-First-Participants-Dosed-in-MRT-6160-Phase-1-Study.html",
        "type": "GLUE"
      },
      {
        "title": "Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day - GlobeNewswire",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-07-08T12:38:14Z",
        "url": "https://www.globenewswire.com/news-release/2024/07/08/2909643/0/en/Monte-Rosa-Therapeutics-to-Present-at-the-UBS-Targeted-Protein-Degradation-Day.html",
        "type": "GLUE"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": null,
        "forwardPE": -4.1745276
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  },
  {
    "symbol": "GMAB",
    "timestamp": "2025-02-04 08:51:09",
    "names": {
      "long": "Genmab A/S",
      "short": "Genmab A/S",
      "polygon": "Genmab A/S ADS"
    },
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "description": "Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.",
    "branding": {
      "icon_url": "https://api.polygon.io/v1/reference/company-branding/Z2VubWFiLmNvbQ/images/2024-10-01_icon.png?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq",
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/Z2VubWFiLmNvbQ/images/2024-10-01_logo.svg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "investing_url": "https://www.investing.com/equities/genmab",
    "price": 19.33,
    "priceChange": 1.1512297226582882,
    "openPrice": 19.19,
    "prevClose": 19.11,
    "dayHigh": 19.43,
    "dayLow": 19.13,
    "volume": 463893,
    "prevVolume": 1177371.0,
    "volumeMetrics": {
      "recentVolumes": [
        5346723.0,
        1262850.0,
        1316499.0,
        1177371.0,
        463893
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        -76.38,
        4.25,
        -10.57,
        -60.6
      ],
      "averageVolume": 1320107.6333333333,
      "volumeChange": -60.6,
      "volumeVsAvg": -64.86
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 1320107.6333333333
    },
    "fiftyTwoWeekHigh": 31.88,
    "fiftyTwoWeekLow": 19.0,
    "highProximityPct": 39.366373902133,
    "marketCap": 12317299140.300001,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": [],
      "summary": {
        "total_sales": 0,
        "total_purchases": 0,
        "total_awards": 0,
        "sales_count": 0,
        "purchases_count": 0,
        "awards_count": 0
      }
    },
    "recentNews": [
      {
        "title": "Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2025-01-03T18:56:00Z",
        "url": "https://www.globenewswire.com/news-release/2025/01/03/3004126/0/en/Genmab-to-Present-at-the-43rd-Annual-J-P-Morgan-Healthcare-Conference.html",
        "type": "GMAB"
      },
      {
        "title": "Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody\u00ae CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-12-09T17:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/12/09/2993970/0/en/Two-Data-Analyses-from-Clinical-Trials-Show-Epcoritamab-DuoBody-CD3xCD20-Induces-Durable-Complete-Responses-as-Monotherapy-and-Combination-Treatment-in-Patients-With-Diffuse-Large-.html",
        "type": "GMAB"
      },
      {
        "title": "CD40 Targeted Therapies Clinical Trials & Market Opportunity Report 2025,  Insight By Company, Country, Indication & Phase",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-12-09T09:48:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/12/09/2993524/28124/en/CD40-Targeted-Therapies-Clinical-Trials-Market-Opportunity-Report-2025-Insight-By-Company-Country-Indication-Phase.html",
        "type": "AMGN"
      },
      {
        "title": "Investigational Epcoritamab (DuoBody\u00ae CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-12-08T00:12:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/12/08/2993359/0/en/Investigational-Epcoritamab-DuoBody-CD3xCD20-Combination-Therapy-Demonstrates-High-Response-Rates-in-Clinical-Trial-of-Patients-With-Relapsed-or-Refractory-R-R-Follicular-Lymphoma-.html",
        "type": "GMAB"
      },
      {
        "title": "Grant of Restricted Stock Units and Warrants to Employees in Genmab",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-11-21T19:48:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/11/21/2985567/0/en/Grant-of-Restricted-Stock-Units-and-Warrants-to-Employees-in-Genmab.html",
        "type": "GMAB"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": 19.118912,
        "forwardPE": 12.724356
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  },
  {
    "symbol": "GNPX",
    "timestamp": "2025-02-04 08:51:11",
    "names": {
      "long": "Genprex, Inc.",
      "short": "Genprex, Inc.",
      "polygon": "Genprex, Inc. Common Stock"
    },
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "description": "Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.",
    "branding": {
      "icon_url": "https://api.polygon.io/v1/reference/company-branding/Z2VucHJleC5jb20/images/2024-10-01_icon.jpeg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq",
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/Z2VucHJleC5jb20/images/2024-10-01_logo.svg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "investing_url": "https://www.investing.com/equities/genprex",
    "price": 0.525,
    "priceChange": -7.910892825820036,
    "openPrice": 0.563,
    "prevClose": 0.5701,
    "dayHigh": 0.57,
    "dayLow": 0.4711,
    "volume": 366456,
    "prevVolume": 221492,
    "volumeMetrics": {
      "recentVolumes": [
        78192,
        171016,
        264481,
        221492,
        366456
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        118.71,
        54.65,
        -16.25,
        65.45
      ],
      "averageVolume": 990997.0166666667,
      "volumeChange": 65.45,
      "volumeVsAvg": -63.02
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 990997.0166666667
    },
    "fiftyTwoWeekHigh": 6.49,
    "fiftyTwoWeekLow": 0.281,
    "highProximityPct": 91.91063174114021,
    "marketCap": 4635195.4464,
    "insiderActivity": {
      "recent_trades": 5,
      "net_shares": 61875,
      "notable_trades": [],
      "summary": {
        "total_sales": 0,
        "total_purchases": 61875,
        "total_awards": 0,
        "sales_count": 0,
        "purchases_count": 5,
        "awards_count": 0,
        "total_value": {
          "sales": 0.0,
          "purchases": 0.0,
          "awards": 0.0
        }
      },
      "latest_date": "2024-12-05"
    },
    "recentNews": [
      {
        "title": "Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa\u00ae Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics",
        "publisher": "Benzinga",
        "timestamp": "2024-09-09T13:29:00Z",
        "url": "https://www.benzinga.com/pressreleases/24/09/n40773728/genprex-collaborators-to-present-positive-preclinical-data-on-the-use-of-reqorsa-gene-therapy-at-t",
        "type": "GNPX"
      },
      {
        "title": "Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up",
        "publisher": "Zacks Investment Research",
        "timestamp": "2024-04-04T12:57:00Z",
        "url": "https://www.zacks.com/stock/news/2250526/genprex-gnpx-expands-sclc-study-of-key-candidate-stock-up",
        "type": "AZN"
      },
      {
        "title": "Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session",
        "publisher": "Benzinga",
        "timestamp": "2024-03-06T18:54:52Z",
        "url": "https://www.benzinga.com/news/24/03/37517720/why-united-natural-foods-shares-are-trading-lower-by-15-here-are-other-stocks-moving-in-wednesdays-m",
        "type": "BASE"
      },
      {
        "title": "Dow Turns Lower; Federal Reserve Keeps Rates Unchanged",
        "publisher": "Benzinga",
        "timestamp": "2024-01-31T19:26:51Z",
        "url": "https://www.benzinga.com/news/earnings/24/01/36874214/dow-turns-lower-fed-keeps-rates-unchanged",
        "type": "POWL"
      },
      {
        "title": "Why AMD Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session",
        "publisher": "Benzinga",
        "timestamp": "2024-01-31T18:18:09Z",
        "url": "https://www.benzinga.com/news/24/01/36872881/why-amd-shares-are-trading-lower-here-are-other-stocks-moving-in-wednesdays-mid-day-session",
        "type": "LXU"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": null,
        "forwardPE": -0.41904002
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 4,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  },
  {
    "symbol": "GRTX",
    "timestamp": "2025-02-04 08:51:15",
    "names": {
      "long": "Galera Therapeutics, Inc.",
      "short": "Galera Therapeutics, Inc.",
      "polygon": "GALERA THERAPEUTICS INC"
    },
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "description": null,
    "branding": {
      "icon_url": null,
      "logo_url": null
    },
    "investing_url": "https://www.investing.com/equities/galera-therapeutics-inc",
    "price": 0.0453,
    "priceChange": 0.0,
    "openPrice": 0.0451,
    "prevClose": 0.0453,
    "dayHigh": 0.0475,
    "dayLow": 0.0451,
    "volume": 5725,
    "prevVolume": 82393,
    "volumeMetrics": {
      "recentVolumes": [
        180000,
        61183,
        24913,
        82393,
        5725
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        -66.01,
        -59.28,
        230.72,
        -93.05
      ],
      "averageVolume": 210166.41666666666,
      "volumeChange": -93.05,
      "volumeVsAvg": -97.28
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 210166.41666666666
    },
    "fiftyTwoWeekHigh": 0.29,
    "fiftyTwoWeekLow": 0.021,
    "highProximityPct": 84.37931034482759,
    "marketCap": 0,
    "insiderActivity": {
      "recent_trades": 1,
      "net_shares": 7644932,
      "notable_trades": [
        {
          "date": "2024-12-30",
          "insider": "CHANG NANCY T",
          "position": "Director and Beneficial Owner of more than 10% of a Class of Security",
          "type": "Stock Award",
          "shares": 7644932,
          "value": 206413.0,
          "price_per_share": 0.026999978547879826
        }
      ],
      "summary": {
        "total_sales": 0,
        "total_purchases": 0,
        "total_awards": 7644932,
        "sales_count": 0,
        "purchases_count": 0,
        "awards_count": 1,
        "total_value": {
          "sales": 0.0,
          "purchases": 0.0,
          "awards": 206413.0
        }
      },
      "latest_date": "2024-12-30"
    },
    "recentNews": [
      {
        "title": "Kailera Therapeutics Launches with $400 Million Series A Financing to Advance Portfolio of Next-Generation Therapies for Obesity and Related Conditions",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-10-01T11:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/10/01/2955962/0/en/Kailera-Therapeutics-Launches-with-400-Million-Series-A-Financing-to-Advance-Portfolio-of-Next-Generation-Therapies-for-Obesity-and-Related-Conditions.html",
        "type": "GRTX"
      },
      {
        "title": "Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-05-13T11:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/05/13/2880268/0/en/Galera-Reports-First-Quarter-2024-Financial-Results-and-Recent-Corporate-Updates.html",
        "type": "GRTX"
      },
      {
        "title": "Galera Adopts Limited Duration Stockholder Rights Agreement",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-05-03T11:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/05/03/2875022/0/en/Galera-Adopts-Limited-Duration-Stockholder-Rights-Agreement.html",
        "type": "GRTX"
      },
      {
        "title": "Why Doma Holdings Shares Are Trading Higher By Around 34%; Here Are 20 Stocks Moving Premarket",
        "publisher": "Benzinga",
        "timestamp": "2024-04-01T12:08:35Z",
        "url": "https://www.benzinga.com/news/24/04/38020324/why-doma-holdings-shares-are-trading-higher-by-around-34-here-are-20-stocks-moving-premarket",
        "type": "DOMA"
      },
      {
        "title": "Why TransMedics Group Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket",
        "publisher": "Benzinga",
        "timestamp": "2024-02-27T12:56:22Z",
        "url": "https://www.benzinga.com/news/24/02/37332809/why-transmedics-group-shares-are-trading-higher-by-around-23-here-are-20-stocks-moving-premarket",
        "type": "PEGY"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": null,
        "forwardPE": -0.036370967
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 2,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": true,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  },
  {
    "symbol": "GUTS",
    "timestamp": "2025-02-04 08:51:17",
    "names": {
      "long": "Fractyl Health, Inc.",
      "short": "Fractyl Health, Inc.",
      "polygon": "Fractyl Health, Inc. Common Stock"
    },
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "description": "Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.",
    "branding": {
      "icon_url": "https://api.polygon.io/v1/reference/company-branding/ZnJhY3R5bC5jb20/images/2024-10-01_icon.jpeg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq",
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/ZnJhY3R5bC5jb20/images/2024-10-01_logo.png?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "investing_url": "https://www.investing.com/equities/fractyl-health-consensus-estimates",
    "price": 1.6574,
    "priceChange": -2.5058823529411747,
    "openPrice": 1.7,
    "prevClose": 1.7,
    "dayHigh": 1.78,
    "dayLow": 1.65,
    "volume": 230547,
    "prevVolume": 581872,
    "volumeMetrics": {
      "recentVolumes": [
        156530,
        207002,
        1191096.0,
        581872,
        230547
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        32.24,
        475.4,
        -51.15,
        -60.38
      ],
      "averageVolume": 348601.88333333336,
      "volumeChange": -60.38,
      "volumeVsAvg": -33.87
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 348601.88333333336
    },
    "fiftyTwoWeekHigh": 11.554,
    "fiftyTwoWeekLow": 1.63,
    "highProximityPct": 85.65518435173965,
    "marketCap": 82008699.52000001,
    "insiderActivity": {
      "recent_trades": 8,
      "net_shares": 876371,
      "notable_trades": [
        {
          "date": "2025-01-31",
          "insider": "RAJAGOPALAN HARITH M.D., PH.D.",
          "position": "Chief Executive Officer",
          "type": "Stock Award",
          "shares": 111920,
          "value": 206003.0,
          "price_per_share": 1.8406272337383847
        },
        {
          "date": "2025-01-31",
          "insider": "RAJAGOPALAN HARITH M.D., PH.D.",
          "position": "Chief Executive Officer",
          "type": "Stock Award",
          "shares": 111920,
          "value": 190264.0,
          "price_per_share": 1.7
        },
        {
          "date": "2024-11-11",
          "insider": "CAPLAN JAY DAVID",
          "position": "President",
          "type": "Stock Award",
          "shares": 64197,
          "value": 158541.0,
          "price_per_share": 2.4696013832422077
        },
        {
          "date": "2024-11-11",
          "insider": "RAJAGOPALAN HARITH M.D., PH.D.",
          "position": "Chief Executive Officer",
          "type": "Stock Award",
          "shares": 96517,
          "value": 238358.0,
          "price_per_share": 2.4695960297149724
        }
      ],
      "summary": {
        "total_sales": 0,
        "total_purchases": 404181,
        "total_awards": 472190,
        "sales_count": 0,
        "purchases_count": 2,
        "awards_count": 6,
        "total_value": {
          "sales": 0.0,
          "purchases": 0.0,
          "awards": 949923.0
        }
      },
      "latest_date": "2025-01-31"
    },
    "recentNews": [
      {
        "title": "Fractyl Health to Participate in the Upcoming December Conferences",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-11-26T12:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/11/26/2987332/0/en/Fractyl-Health-to-Participate-in-the-Upcoming-December-Conferences.html",
        "type": "GUTS"
      },
      {
        "title": "Fractyl Health to Report Third Quarter 2024 Financial Results and Provide Business Updates on November 12, 2024",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-10-29T11:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/10/29/2970640/0/en/Fractyl-Health-to-Report-Third-Quarter-2024-Financial-Results-and-Provide-Business-Updates-on-November-12-2024.html",
        "type": "GUTS"
      },
      {
        "title": "Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-06-25T11:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/06/25/2903644/0/en/Fractyl-Health-to-Present-at-Piper-Sandler-2nd-Annual-Virtual-Obesity-Day.html",
        "type": "GUTS"
      },
      {
        "title": "Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-06-24T10:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/06/24/2902818/0/en/Fractyl-Health-Announces-Advancement-in-Weight-Maintenance-Pipeline-and-Business-Updates.html",
        "type": "GUTS"
      },
      {
        "title": "Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva\u00ae Single-Administration GLP-1 Pancreatic Gene Therapy in President\u2019s Select Oral Presentation at the American Diabetes Association\u2019s 84th Scientific Sessions",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-06-23T17:30:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/06/23/2902704/0/en/Fractyl-Health-Presents-New-Preclinical-Data-on-Sustained-Weight-Maintenance-and-Improved-Body-Composition-from-its-Rejuva-Single-Administration-GLP-1-Pancreatic-Gene-Therapy-in-Pr.html",
        "type": "GUTS"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": null,
        "forwardPE": -0.9060774
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 2,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": true,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  },
  {
    "symbol": "GYRE",
    "timestamp": "2025-02-04 08:51:20",
    "names": {
      "long": "Gyre Therapeutics, Inc.",
      "short": "Gyre Therapeutics, Inc.",
      "polygon": "Gyre Therapeutics, Inc. Common Stock"
    },
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "description": "Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.",
    "branding": {
      "icon_url": null,
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/Z3lyZXR4LmNvbQ/images/2024-10-01_logo.svg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "investing_url": "https://www.investing.com/equities/targacept",
    "price": 11.595,
    "priceChange": 0.21607605877269104,
    "openPrice": 11.6,
    "prevClose": 11.57,
    "dayHigh": 11.71,
    "dayLow": 11.35,
    "volume": 11458,
    "prevVolume": 54094,
    "volumeMetrics": {
      "recentVolumes": [
        67677,
        64680,
        41413,
        54094,
        11458
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        -4.43,
        -35.97,
        30.62,
        -78.82
      ],
      "averageVolume": 110093.56666666667,
      "volumeChange": -78.82,
      "volumeVsAvg": -89.59
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 110093.56666666667
    },
    "fiftyTwoWeekHigh": 26.37,
    "fiftyTwoWeekLow": 8.26,
    "highProximityPct": 56.02957906712172,
    "marketCap": 987814350.72,
    "insiderActivity": {
      "recent_trades": 14,
      "net_shares": 51329,
      "notable_trades": [],
      "summary": {
        "total_sales": 0,
        "total_purchases": 0,
        "total_awards": 51329,
        "sales_count": 0,
        "purchases_count": 0,
        "awards_count": 14,
        "total_value": {
          "sales": 0.0,
          "purchases": 0.0,
          "awards": 579920.0
        }
      },
      "latest_date": "2025-01-30"
    },
    "recentNews": [
      {
        "title": "Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-06-18T20:05:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/06/18/2900811/0/en/Gyre-Therapeutics-Announces-Publication-in-Journal-of-Gastroenterology-and-Hepatology.html",
        "type": "GYRE"
      },
      {
        "title": "Gyre Therapeutics Announces Expected Addition to the Russell 2000\u00ae and Russell 3000\u00ae Indexes",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-05-28T20:05:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/05/28/2889411/0/en/Gyre-Therapeutics-Announces-Expected-Addition-to-the-Russell-2000-and-Russell-3000-Indexes.html",
        "type": "GYRE"
      },
      {
        "title": "Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-05-09T20:10:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/05/09/2879221/0/en/Gyre-Therapeutics-Reports-First-Quarter-2024-Financial-Results-and-Provides-Business-Update.html",
        "type": "GYRE"
      },
      {
        "title": "Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session",
        "publisher": "Benzinga",
        "timestamp": "2024-04-11T17:33:07Z",
        "url": "https://www.benzinga.com/news/24/04/38208091/why-fastenal-shares-are-trading-lower-by-around-7-here-are-other-stocks-moving-in-thursdays-mid-day",
        "type": "APVO"
      },
      {
        "title": "Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday",
        "publisher": "Benzinga",
        "timestamp": "2024-04-11T14:01:51Z",
        "url": "https://www.benzinga.com/news/24/04/38203373/enliven-therapeutics-alpine-immune-sciences-janux-therapeutics-and-other-big-stocks-moving-higher-on",
        "type": "ALTI"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": null,
        "forwardPE": 25.184782
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  },
  {
    "symbol": "HALO",
    "timestamp": "2025-02-04 08:51:23",
    "names": {
      "long": "Halozyme Therapeutics, Inc.",
      "short": "Halozyme Therapeutics, Inc.",
      "polygon": "Halozyme Therapeutics, Inc."
    },
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "description": "Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.",
    "branding": {
      "icon_url": "https://api.polygon.io/v1/reference/company-branding/aGFsb3p5bWUuY29t/images/2024-10-01_icon.jpeg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq",
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/aGFsb3p5bWUuY29t/images/2024-10-01_logo.svg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "investing_url": "https://www.investing.com/equities/halo-technologies-holdings-scoreboard",
    "price": 56.69,
    "priceChange": 0.728500355366021,
    "openPrice": 56.01,
    "prevClose": 56.28,
    "dayHigh": 56.785,
    "dayLow": 55.925,
    "volume": 171674,
    "prevVolume": 1078546.0,
    "volumeMetrics": {
      "recentVolumes": [
        828153,
        1050942.0,
        1348909.0,
        1078546.0,
        171674
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        26.9,
        28.35,
        -20.04,
        -84.08
      ],
      "averageVolume": 1584688.6333333333,
      "volumeChange": -84.08,
      "volumeVsAvg": -89.17
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 1584688.6333333333
    },
    "fiftyTwoWeekHigh": 65.53,
    "fiftyTwoWeekLow": 33.64,
    "highProximityPct": 13.490004578055858,
    "marketCap": 7217587710.0,
    "insiderActivity": {
      "recent_trades": 4,
      "net_shares": 18081,
      "notable_trades": [
        {
          "date": "2025-01-06",
          "insider": "HENDERSON JEFFREY WILLIAM",
          "position": "Director",
          "type": "Sale",
          "shares": 10000,
          "value": 500060.0,
          "price_per_share": 50.006
        }
      ],
      "summary": {
        "total_sales": 10000,
        "total_purchases": 28081,
        "total_awards": 0,
        "sales_count": 1,
        "purchases_count": 3,
        "awards_count": 0,
        "total_value": {
          "sales": 500060.0,
          "purchases": 0.0,
          "awards": 0.0
        }
      },
      "latest_date": "2025-01-06"
    },
    "recentNews": [
      {
        "title": "Needle Free Injectors Market Is Expected To Reach a Revenue Of USD 2,980.9 Million By 2033, At 8.1% CAGR: Dimension Market Research",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-11-11T16:59:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/11/11/2978481/0/en/Needle-Free-Injectors-Market-Is-Expected-To-Reach-a-Revenue-Of-USD-2-980-9-Million-By-2033-At-8-1-CAGR-Dimension-Market-Research.html",
        "type": "GRRMY"
      },
      {
        "title": "Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio",
        "publisher": "Zacks Investment Research",
        "timestamp": "2024-06-27T13:50:11Z",
        "url": "https://www.zacks.com/stock/news/2294347/why-this-1-momentum-stock-could-be-a-great-addition-to-your-portfolio",
        "type": "HALO"
      },
      {
        "title": "Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick",
        "publisher": "Zacks Investment Research",
        "timestamp": "2024-06-20T13:45:09Z",
        "url": "https://www.zacks.com/stock/news/2290898/are-you-a-growth-investor-this-1-stock-could-be-the-perfect-pick",
        "type": "HALO"
      },
      {
        "title": "Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock",
        "publisher": "Zacks Investment Research",
        "timestamp": "2024-06-17T13:40:11Z",
        "url": "https://www.zacks.com/stock/news/2289149/heres-why-halozyme-therapeutics-halo-is-a-strong-value-stock",
        "type": "HALO"
      },
      {
        "title": "Why Is Kodiak Sciences (KOD) Down 26.2% Since Last Earnings Report?",
        "publisher": "Zacks Investment Research",
        "timestamp": "2024-06-14T15:30:06Z",
        "url": "https://www.zacks.com/stock/news/2288588/why-is-kodiak-sciences-kod-down-262-since-last-earnings-report",
        "type": "KOD"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": 18.740067,
        "forwardPE": 11.2005
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 2,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": true,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  },
  {
    "symbol": "HRMY",
    "timestamp": "2025-02-04 08:51:25",
    "names": {
      "long": "Harmony Biosciences Holdings, Inc.",
      "short": "Harmony Biosciences Holdings, I",
      "polygon": "Harmony Biosciences Holdings, Inc. Common Stock"
    },
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "description": "Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing\u00a0therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.",
    "branding": {
      "icon_url": "https://api.polygon.io/v1/reference/company-branding/aGFybW9ueWJpb3NjaWVuY2VzLmNvbQ/images/2024-10-01_icon.jpeg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq",
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/aGFybW9ueWJpb3NjaWVuY2VzLmNvbQ/images/2024-10-01_logo.png?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "investing_url": "https://www.investing.com/equities/harmony-biosciences-holdings",
    "price": 38.53,
    "priceChange": -0.43927648578811807,
    "openPrice": 38.76,
    "prevClose": 38.7,
    "dayHigh": 39.13,
    "dayLow": 38.071,
    "volume": 82514,
    "prevVolume": 467405,
    "volumeMetrics": {
      "recentVolumes": [
        377262,
        376549,
        445985,
        467405,
        82514
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        -0.19,
        18.44,
        4.8,
        -82.35
      ],
      "averageVolume": 505899.9,
      "volumeChange": -82.35,
      "volumeVsAvg": -83.69
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 505899.9
    },
    "fiftyTwoWeekHigh": 41.61,
    "fiftyTwoWeekLow": 28.14,
    "highProximityPct": 7.4020668108627685,
    "marketCap": 2178025232.43,
    "insiderActivity": {
      "recent_trades": 17,
      "net_shares": -159912,
      "notable_trades": [
        {
          "date": "2025-01-27",
          "insider": "DIERKS JEFFREY G",
          "position": "Officer",
          "type": "Sale",
          "shares": 14754,
          "value": 551575.0,
          "price_per_share": 37.38477700962451
        },
        {
          "date": "2025-01-24",
          "insider": "DIERKS JEFFREY G",
          "position": "Officer",
          "type": "Sale",
          "shares": 15812,
          "value": 402806.0,
          "price_per_share": 25.474702757399445
        },
        {
          "date": "2025-01-21",
          "insider": "DAYNO JEFFREY M",
          "position": "Chief Executive Officer",
          "type": "Sale",
          "shares": 19293,
          "value": 774245.0,
          "price_per_share": 40.13087648369875
        },
        {
          "date": "2025-01-21",
          "insider": "KAPADIA SANDIP S.",
          "position": "Chief Financial Officer",
          "type": "Sale",
          "shares": 25000,
          "value": 1004598.0,
          "price_per_share": 40.18392
        },
        {
          "date": "2025-01-21",
          "insider": "DIERKS JEFFREY G",
          "position": "Officer",
          "type": "Sale",
          "shares": 30598,
          "value": 1147715.0,
          "price_per_share": 37.50947774364337
        },
        {
          "date": "2025-01-21",
          "insider": "DAYNO JEFFREY M",
          "position": "Chief Executive Officer",
          "type": "Stock Award",
          "shares": 19293,
          "value": 158588.0,
          "price_per_share": 8.219976157155445
        },
        {
          "date": "2025-01-21",
          "insider": "KAPADIA SANDIP S.",
          "position": "Chief Financial Officer",
          "type": "Sale",
          "shares": 25000,
          "value": 725750.0,
          "price_per_share": 29.03
        },
        {
          "date": "2025-01-21",
          "insider": "DIERKS JEFFREY G",
          "position": "Officer",
          "type": "Sale",
          "shares": 30598,
          "value": 1023197.0,
          "price_per_share": 33.43999607817504
        },
        {
          "date": "2025-01-15",
          "insider": "DIERKS JEFFREY G",
          "position": "Officer",
          "type": "Sale",
          "shares": 10507,
          "value": 388841.0,
          "price_per_share": 37.007804320928905
        },
        {
          "date": "2025-01-15",
          "insider": "DIERKS JEFFREY G",
          "position": "Officer",
          "type": "Sale",
          "shares": 10507,
          "value": 351354.0,
          "price_per_share": 33.439992386028365
        },
        {
          "date": "2025-01-13",
          "insider": "DIERKS JEFFREY G",
          "position": "Officer",
          "type": "Sale",
          "shares": 7180,
          "value": 265946.0,
          "price_per_share": 37.03983286908078
        },
        {
          "date": "2025-01-13",
          "insider": "DIERKS JEFFREY G",
          "position": "Officer",
          "type": "Sale",
          "shares": 7180,
          "value": 240099.0,
          "price_per_share": 33.4399721448468
        }
      ],
      "summary": {
        "total_sales": 198204,
        "total_purchases": 18999,
        "total_awards": 19293,
        "sales_count": 12,
        "purchases_count": 4,
        "awards_count": 1,
        "total_value": {
          "sales": 6943673.0,
          "purchases": 0.0,
          "awards": 158588.0
        }
      },
      "latest_date": "2025-01-27"
    },
    "recentNews": [
      {
        "title": "5-HT2 Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2025-01-22T18:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2025/01/22/3013790/0/en/5-HT2-Agonist-Clinical-Trial-Pipeline-Appears-Robust-With-20-Key-Pharma-Companies-Actively-Working-in-the-Therapeutics-Segment-DelveInsight.html",
        "type": "CYBN"
      },
      {
        "title": "Comprehensive Market Analysis of Latest Published 9 Rare Genetic Disorders Reports | DelveInsight",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-12-19T18:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/12/19/3000169/0/en/Comprehensive-Market-Analysis-of-Latest-Published-9-Rare-Genetic-Disorders-Reports-DelveInsight.html",
        "type": "ELOX"
      },
      {
        "title": "Dravet Syndrome Drug Pipeline Research Report 2024: Therapeutic Assessment, Emerging Drugs, Pipeline Development Activities, Competitive Landscape",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-10-14T14:46:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/10/14/2962675/28124/en/Dravet-Syndrome-Drug-Pipeline-Research-Report-2024-Therapeutic-Assessment-Emerging-Drugs-Pipeline-Development-Activities-Competitive-Landscape.html",
        "type": "HRMY"
      },
      {
        "title": "Harmony Biosciences Holdings, Inc. (HRMY) Surpasses Q2 Earnings and Revenue Estimates",
        "publisher": "Zacks Investment Research",
        "timestamp": "2024-08-06T12:45:04Z",
        "url": "https://www.zacks.com/stock/news/2316766/harmony-biosciences-holdings-inc-hrmy-surpasses-q2-earnings-and-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2316766",
        "type": "HRMY"
      },
      {
        "title": "Praxis Precision Medicines (PRAX) Surges 6.4%: Is This an Indication of Further Gains?",
        "publisher": "Zacks Investment Research",
        "timestamp": "2024-06-21T07:32:00Z",
        "url": "https://www.zacks.com/stock/news/2291181/praxis-precision-medicines-prax-surges-64-is-this-an-indication-of-further-gains",
        "type": "PRAX"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": 18.236967,
        "forwardPE": 8.853487
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 2,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": true,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  },
  {
    "symbol": "IDYA",
    "timestamp": "2025-02-04 08:51:28",
    "names": {
      "long": "IDEAYA Biosciences, Inc.",
      "short": "IDEAYA Biosciences, Inc.",
      "polygon": "IDEAYA Biosciences, Inc. Common Stock"
    },
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "description": "IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.",
    "branding": {
      "icon_url": "https://api.polygon.io/v1/reference/company-branding/aWRlYXlhYmlvLmNvbQ/images/2024-10-01_icon.jpeg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq",
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/aWRlYXlhYmlvLmNvbQ/images/2024-10-01_logo.svg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "investing_url": "https://www.investing.com/equities/ideaya-biosciences-inc",
    "price": 24.14,
    "priceChange": 2.1150592216582065,
    "openPrice": 23.61,
    "prevClose": 23.64,
    "dayHigh": 24.31,
    "dayLow": 23.31,
    "volume": 112997,
    "prevVolume": 540795,
    "volumeMetrics": {
      "recentVolumes": [
        662190,
        1080783.0,
        952993,
        540795,
        112997
      ],
      "volumeDates": [
        "2025-01-28",
        "2025-01-29",
        "2025-01-30",
        "2025-02-02",
        "2025-02-03"
      ],
      "dailyChanges": [
        63.21,
        -11.82,
        -43.25,
        -79.11
      ],
      "averageVolume": 853763.1833333333,
      "volumeChange": -79.11,
      "volumeVsAvg": -86.76
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 853763.1833333333
    },
    "fiftyTwoWeekHigh": 47.735,
    "fiftyTwoWeekLow": 22.1,
    "highProximityPct": 49.429140043992874,
    "marketCap": 2087327945.85,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": [],
      "summary": {
        "total_sales": 0,
        "total_purchases": 0,
        "total_awards": 0,
        "sales_count": 0,
        "purchases_count": 0,
        "awards_count": 0
      }
    },
    "recentNews": [
      {
        "title": "Kura Sushi Posts Weak Q3 Results, Joins LegalZoom.com And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga",
        "publisher": "Benzinga",
        "timestamp": "2024-07-10T12:01:12Z",
        "url": "https://www.benzinga.com/news/24/07/39706881/kura-sushi-posts-weak-q3-results-joins-legalzoom-com-and-other-big-stocks-moving-lower-in-wednesdays",
        "type": "KRUS"
      },
      {
        "title": "Company News for July 9, 2024 - July 9, 2024 - Zacks Investment Research",
        "publisher": "Zacks Investment Research",
        "timestamp": "2024-07-09T12:31:34Z",
        "url": "https://www.zacks.com/stock/news/2298393/company-news-for-july-9-2024",
        "type": "MORF"
      },
      {
        "title": "BTIG lifts Ideaya Biosciences target to $62 on study data - Investing.com",
        "publisher": "Investing.com",
        "timestamp": "2024-07-08T20:17:56Z",
        "url": "https://www.investing.com/news/company-news/btig-lifts-ideaya-biosciences-target-to-62-on-study-data-93CH-3510707",
        "type": "IDYA"
      },
      {
        "title": "Why Paramount Global Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - Paramount ... - Benzinga",
        "publisher": "Benzinga",
        "timestamp": "2024-07-08T09:40:41Z",
        "url": "https://www.benzinga.com/24/07/39660340/why-paramount-global-shares-are-trading-higher-by-around-8-here-are-20-stocks-moving-premarket",
        "type": "PARA"
      },
      {
        "title": "Unveiling 5 Analyst Insights On IDEAYA Biosciences",
        "publisher": "Benzinga",
        "timestamp": "2024-05-08T17:01:09Z",
        "url": "https://www.benzinga.com/insights/analyst-ratings/24/05/38708159/unveiling-5-analyst-insights-on-ideaya-biosciences",
        "type": "IDYA"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": null,
        "forwardPE": -8.916671
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [],
        "revenueChanges": [],
        "netIncome": [],
        "netIncomeChanges": [],
        "operatingMargin": [],
        "operatingMarginChanges": [],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": []
      }
    },
    "alerts": 1,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": false,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  }
]